<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Am Heart Assoc</journal-id><journal-id journal-id-type="iso-abbrev">J Am Heart Assoc</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)2047-9980</journal-id><journal-id journal-id-type="publisher-id">JAH3</journal-id><journal-id journal-id-type="hwp">ahaoa</journal-id><journal-title-group><journal-title>Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease</journal-title></journal-title-group><issn pub-type="epub">2047-9980</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28733430</article-id><article-id pub-id-type="pmc">5586287</article-id><article-id pub-id-type="doi">10.1161/JAHA.117.005549</article-id><article-id pub-id-type="publisher-id">JAH32370</article-id><article-categories><subj-group subj-group-type="overline"><subject>Original Research</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Research</subject><subj-group subj-group-type="heading"><subject>Arrhythmia and Electrophysiology</subject></subj-group></subj-group></article-categories><title-group><article-title>Atherogenic Lipoprotein Determinants of Cardiovascular Disease and Residual Risk Among Individuals With Low Low&#x02010;Density Lipoprotein Cholesterol</article-title><alt-title alt-title-type="left-running-head">Lawler et&#x000a0;al</alt-title></title-group><contrib-group><contrib id="jah32370-cr-0001" contrib-type="author"><name><surname>Lawler</surname><given-names>Patrick R.</given-names></name><degrees>MD, MPH</degrees><xref ref-type="aff" rid="jah32370-aff-0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="jah32370-aff-0002">
<sup>2</sup>
</xref><xref ref-type="aff" rid="jah32370-aff-0003">
<sup>3</sup>
</xref><xref ref-type="aff" rid="jah32370-aff-0004">
<sup>4</sup>
</xref><xref ref-type="aff" rid="jah32370-aff-0005">
<sup>5</sup>
</xref></contrib><contrib id="jah32370-cr-0002" contrib-type="author"><name><surname>Akinkuolie</surname><given-names>Akintunde O.</given-names></name><degrees>MBBS, MPH</degrees><xref ref-type="aff" rid="jah32370-aff-0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="jah32370-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="jah32370-cr-0003" contrib-type="author"><name><surname>Chu</surname><given-names>Audrey Y.</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="jah32370-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="jah32370-cr-0004" contrib-type="author"><name><surname>Shah</surname><given-names>Svati H.</given-names></name><degrees>MD, MHS</degrees><xref ref-type="aff" rid="jah32370-aff-0006">
<sup>6</sup>
</xref></contrib><contrib id="jah32370-cr-0005" contrib-type="author"><name><surname>Kraus</surname><given-names>William E.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="jah32370-aff-0006">
<sup>6</sup>
</xref></contrib><contrib id="jah32370-cr-0006" contrib-type="author"><name><surname>Craig</surname><given-names>Damian</given-names></name><degrees>MSc</degrees><xref ref-type="aff" rid="jah32370-aff-0006">
<sup>6</sup>
</xref></contrib><contrib id="jah32370-cr-0007" contrib-type="author"><name><surname>Padmanabhan</surname><given-names>Latha</given-names></name><degrees>MSc</degrees><xref ref-type="aff" rid="jah32370-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="jah32370-cr-0008" contrib-type="author"><name><surname>Glynn</surname><given-names>Robert J.</given-names></name><degrees>ScD</degrees><xref ref-type="aff" rid="jah32370-aff-0002">
<sup>2</sup>
</xref><xref ref-type="aff" rid="jah32370-aff-0003">
<sup>3</sup>
</xref><xref ref-type="aff" rid="jah32370-aff-0007">
<sup>7</sup>
</xref></contrib><contrib id="jah32370-cr-0009" contrib-type="author"><name><surname>Ridker</surname><given-names>Paul M</given-names></name><degrees>MD, MPH</degrees><xref ref-type="aff" rid="jah32370-aff-0002">
<sup>2</sup>
</xref><xref ref-type="aff" rid="jah32370-aff-0003">
<sup>3</sup>
</xref><xref ref-type="aff" rid="jah32370-aff-0007">
<sup>7</sup>
</xref></contrib><contrib id="jah32370-cr-0010" contrib-type="author"><name><surname>Chasman</surname><given-names>Daniel I.</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="jah32370-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="jah32370-cr-0011" contrib-type="author" corresp="yes"><name><surname>Mora</surname><given-names>Samia</given-names></name><degrees>MD, MHS</degrees><address><email>smora@partners.org</email></address><xref ref-type="aff" rid="jah32370-aff-0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="jah32370-aff-0002">
<sup>2</sup>
</xref><xref ref-type="aff" rid="jah32370-aff-0003">
<sup>3</sup>
</xref></contrib></contrib-group><aff id="jah32370-aff-0001">
<label><sup>1</sup></label>
<named-content content-type="organisation-division">Center for Lipid Metabolomics</named-content>
<named-content content-type="organisation-division">Brigham and Women's Hospital</named-content>
<institution>Harvard Medical School</institution>
<named-content content-type="city">Boston</named-content>
<named-content content-type="country-part">MA</named-content>
</aff><aff id="jah32370-aff-0002">
<label><sup>2</sup></label>
<named-content content-type="organisation-division">Cardiovascular Division</named-content>
<named-content content-type="organisation-division">Brigham and Women's Hospital</named-content>
<institution>Harvard Medical School</institution>
<named-content content-type="city">Boston</named-content>
<named-content content-type="country-part">MA</named-content>
</aff><aff id="jah32370-aff-0003">
<label><sup>3</sup></label>
<named-content content-type="organisation-division">Preventive Medicine Division</named-content>
<named-content content-type="organisation-division">Brigham and Women's Hospital</named-content>
<institution>Harvard Medical School</institution>
<named-content content-type="city">Boston</named-content>
<named-content content-type="country-part">MA</named-content>
</aff><aff id="jah32370-aff-0004">
<label><sup>4</sup></label>
<named-content content-type="organisation-division">Peter Munk Cardiac Centre</named-content>
<institution>University Health Network</institution>
<named-content content-type="city">Toronto</named-content>
<named-content content-type="country-part">Ontario</named-content>
<country country="CA">Canada</country>
</aff><aff id="jah32370-aff-0005">
<label><sup>5</sup></label>
<named-content content-type="organisation-division">Heart and Stroke Richard Lewar Centre of Excellence in Cardiovascular Research</named-content>
<institution>University of Toronto</institution>
<named-content content-type="country-part">Ontario</named-content>
<country country="CA">Canada</country>
</aff><aff id="jah32370-aff-0006">
<label><sup>6</sup></label>
<named-content content-type="organisation-division">Division of Cardiology and Duke Molecular Physiology Institute</named-content>
<institution>Duke University School of Medicine</institution>
<named-content content-type="city">Durham</named-content>
<named-content content-type="country-part">NC</named-content>
</aff><aff id="jah32370-aff-0007">
<label><sup>7</sup></label>
<institution>Harvard T. H. Chan School of Public Health</institution>
<named-content content-type="city">Boston</named-content>
<named-content content-type="country-part">MA</named-content>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence to:</bold> Samia Mora, MD, MHS, Brigham and Women's Hospital, 900 Commonwealth Avenue East, Boston, MA 02215. E&#x02010;mail: <email>smora@partners.org</email></corresp></author-notes><pub-date pub-type="epub"><day>21</day><month>7</month><year>2017</year></pub-date><pub-date pub-type="collection"><month>7</month><year>2017</year></pub-date><volume>6</volume><issue>7</issue><issue-id pub-id-type="doi">10.1002/jah3.2017.6.issue-7</issue-id><elocation-id>e005549</elocation-id><history><date date-type="received"><day>19</day><month>4</month><year>2017</year></date><date date-type="accepted"><day>23</day><month>5</month><year>2017</year></date></history><permissions><!--<copyright-statement content-type="issue-copyright"> Copyright &#x000a9; 2017 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell <copyright-statement>--><copyright-statement content-type="article-copyright">&#x000a9; 2017 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.</copyright-statement><license license-type="creativeCommonsBy"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:JAH3-6-e005549.pdf"/><abstract id="jah32370-abs-0001"><sec id="jah32370-sec-0001"><title>Background</title><p>Levels of LDL (low&#x02010;density lipoprotein) cholesterol in the population are declining, and increasing attention is being focused on residual lipid&#x02010;related pathways of atherosclerotic cardiovascular disease risk beyond <styled-content style="fixed-case">LDL</styled-content> cholesterol. Among individuals with low (&#x0003c;130&#x000a0;mg/dL) <styled-content style="fixed-case">LDL</styled-content> cholesterol, we undertook detailed profiling of circulating atherogenic lipoproteins in relation to incident cardiovascular disease in 2 populations.</p></sec><sec id="jah32370-sec-0002"><title>Methods and Results</title><p>We performed proton nuclear magnetic resonance spectroscopy to quantify concentrations of <styled-content style="fixed-case">LDL</styled-content> and VLDL (very low&#x02010;density lipoprotein) particle subclasses in 11&#x000a0;984 <styled-content style="fixed-case">JUPITER</styled-content> trial participants (<styled-content style="fixed-case">NCT</styled-content>00239681). Adjusted Cox models examined cardiovascular disease risk associated with lipoprotein measures according to treatment allocation. Risk (adjusted hazard ratio [95%<styled-content style="fixed-case">CI</styled-content>] per <styled-content style="fixed-case">SD</styled-content> increment) among placebo&#x02010;allocated participants was associated with total <styled-content style="fixed-case">LDL</styled-content> particles (1.19 [1.02, 1.38]) and total <styled-content style="fixed-case">VLDL</styled-content> particles (1.21 [1.04, 1.41]), as well as apolipoprotein B, non&#x02013;high&#x02010;density lipoprotein cholesterol, and triglycerides, but not LDL&#x02010;c. Rosuvastatin reduced <styled-content style="fixed-case">LDL</styled-content> measures but had variable effects on triglyceride and <styled-content style="fixed-case">VLDL</styled-content> measures. On&#x02010;statin levels of the smallest <styled-content style="fixed-case">VLDL</styled-content> particle subclass were associated with a 68% per&#x02010;<styled-content style="fixed-case">SD</styled-content> (adjusted hazard ratio 1.68 [1.28, 2.22]) increase in residual risk&#x02014;this risk was related to <styled-content style="fixed-case">VLDL</styled-content> cholesterol and not triglyceride or larger <styled-content style="fixed-case">VLDL</styled-content> particles. There was evidence that residual risk prediction during statin therapy could be significantly improved through the inclusion of key <styled-content style="fixed-case">VLDL</styled-content> measures (Harrell C&#x02010;index 0.780 versus 0.712; <italic>P</italic>&#x0003c;0.0001). In an independent, prospective cohort of 4721 individuals referred for cardiac catheterization (<styled-content style="fixed-case">CATHGEN</styled-content>), similar patterns of lipoprotein&#x02010;related risk were observed.</p></sec><sec id="jah32370-sec-0003"><title>Conclusions</title><p>Atherogenic lipoprotein particle concentrations were associated with cardiovascular disease risk when <styled-content style="fixed-case">LDL</styled-content> cholesterol was low. <styled-content style="fixed-case">VLDL</styled-content> lipoproteins, particularly the smallest remnant subclass, may represent unused targets for risk prediction and potential therapeutic intervention for reducing residual risk.</p></sec><sec id="jah32370-sec-0004"><title>Clinical Trial Registration</title><p>
<styled-content style="fixed-case">URL</styled-content>: <ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov">http://www.clinicaltrials.gov</ext-link>. Unique identifier: <styled-content style="fixed-case">NCT</styled-content>00239681.</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="jah32370-kwd-0001">atherosclerosis</kwd><kwd id="jah32370-kwd-0002">lipids and lipoproteins</kwd><kwd id="jah32370-kwd-0003">metabolomics</kwd><kwd id="jah32370-kwd-0004">nuclear magnetic resonance spectroscopy</kwd><kwd id="jah32370-kwd-0005">prevention</kwd></kwd-group><kwd-group kwd-group-type="subject-categories"><title>Subject Categories</title><kwd>Cardiovascular Disease</kwd><kwd>Lipids and Cholesterol</kwd><kwd>Primary Prevention</kwd><kwd>Atherosclerosis</kwd></kwd-group><funding-group><award-group><funding-source>NIH</funding-source><award-id>HL007575</award-id><award-id>R01HL117861&#x02010;S1 and &#x02010;S2</award-id></award-group><award-group><funding-source>NIH Loan Repayment Program</funding-source></award-group><award-group><funding-source>Brigham and Women's Hospital</funding-source></award-group><award-group><funding-source>Peter Munk Cardiac Centre</funding-source></award-group><award-group><funding-source>University Health Network</funding-source></award-group><award-group><funding-source>University of Toronto</funding-source></award-group><award-group><funding-source>Heart and Stroke/Richard Lewar Center for Excellence in Cardiovascular Research</funding-source></award-group><award-group><funding-source>National Heart, Lung, and Blood Institute of the NIH</funding-source><award-id>R01HL117861</award-id></award-group><award-group><funding-source>Molino Family Trust</funding-source></award-group><award-group><funding-source>AstraZeneca</funding-source></award-group></funding-group><counts><fig-count count="5"/><table-count count="7"/><page-count count="17"/><word-count count="10814"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>component-id</meta-name><meta-value>jah32370</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>July 2017</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:5.1.4 mode:remove_FC converted:25.07.2017</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="jah32370-cit-1001">(<source>J Am Heart Assoc</source>. <year>2017</year>;<volume>6</volume>:<elocation-id>e005549</elocation-id> DOI: <ext-link ext-link-type="doi" xlink:href="10.1161/JAHA.117.005549">10.1161/JAHA.117.005549</ext-link>.)<pub-id pub-id-type="pmid">28733430</pub-id></mixed-citation>
</p></notes></front><body><p>
<boxed-text position="anchor" content-type="box" id="jah32370-blkfxd-0001" orientation="portrait"><sec id="jah32370-sec-0006"><title>Clinical Perspective</title><sec id="jah32370-sec-0007"><title>What Is New?</title><p>
<list list-type="bullet" id="jah32370-list-0001"><list-item><p>Among a population intended to represent the growing number of individuals with low low&#x02010;density lipoprotein cholesterol, atherogenic lipoprotein particle concentrations (low&#x02010;density lipoprotein and very low&#x02010;density lipoprotein particles) were markers of residual atherosclerotic cardiovascular disease risk.</p></list-item><list-item><p>Among individuals with the lowest low&#x02010;density lipoprotein cholesterol on statin, the smallest subclass of very low&#x02010;density lipoprotein was strongly associated with residual risk.</p></list-item><list-item><p>This risk was related to the cholesterol carried in small very low&#x02010;density lipoprotein, and not triglyceride.</p></list-item><list-item><p>Similar patterns were observed in an independent, diverse population of individuals referred for cardiac catheterization at a single center.</p></list-item></list>
</p></sec><sec id="jah32370-sec-0008"><title>What Are the Clinical Implications?</title><p>
<list list-type="bullet" id="jah32370-list-0002"><list-item><p>Species of triglyceride&#x02010;rich lipoproteins (very low&#x02010;density lipoproteins) may represent unused clinical targets for risk prediction and potential therapeutic intervention in the prevention of atherosclerotic cardiovascular disease, particularly among individuals with low&#x02010;density lipoprotein cholesterol reduction on statin.</p></list-item><list-item><p>Triglyceride level may incompletely reflect risk differentially related to triglyceride&#x02010;rich lipoprotein subclasses.</p></list-item><list-item><p>Detailed phenotyping of the circulating lipid and lipoprotein milieu could improve risk assessment, as well as advance the evaluation of emerging therapies to prevent cardiovascular disease.</p></list-item></list>
</p></sec></sec></boxed-text>
</p><sec id="jah32370-sec-0009"><title>Introduction</title><p>Population levels of LDL&#x02010;c (low&#x02010;density lipoprotein cholesterol) are declining with increasing adherence to healthy lifestyle and pharmacologic interventions.<xref rid="jah32370-bib-0001" ref-type="ref">1</xref>, <xref rid="jah32370-bib-0002" ref-type="ref">2</xref> However, cardiovascular disease (CVD) events remain prevalent among individuals with low or normal LDL&#x02010;c, both pretreatment and during high&#x02010;intensity statin therapy,<xref rid="jah32370-bib-0003" ref-type="ref">3</xref> a phenomenon referred to as residual risk. In parallel, as population levels of LDL&#x02010;c have declined over recent years, studies have demonstrated time&#x02010;dependent changes in the composition and morphology of human atherosclerotic plaque,<xref rid="jah32370-bib-0004" ref-type="ref">4</xref> suggesting shifting mechanisms of atherogenesis and plaque disruption amid this changing risk factor exposure and changing epidemiology of CVD.<xref rid="jah32370-bib-0005" ref-type="ref">5</xref> Numerous studies have suggested that LDL&#x02010;c does not account for all of the risk conferred by atherogenic plasma lipids and the insulating lipid and protein assemblies that transport them in the bloodstream, lipoproteins,<xref rid="jah32370-bib-0006" ref-type="ref">6</xref>, <xref rid="jah32370-bib-0007" ref-type="ref">7</xref> and thus, it is possible that residual lipid and lipoprotein risk pathways or markers that were previously eclipsed in significance by LDL&#x02010;c are likely to emerge as increasingly important determinants of CVD.</p><p>To understand the residual markers of lipid&#x02010; and lipoprotein&#x02010;related risk in the era of LDL&#x02010;c reduction and to forecast the emergence of such alternate risk pathways, we examined populations of individuals with low (&#x0003c;130&#x000a0;mg/dL) LDL&#x02010;c with advanced lipoprotein profiling. Detailed lipoprotein phenotyping by proton nuclear magnetic resonance (<sup>1</sup>H NMR) spectroscopy can quantify concentrations, subclass distributions, composition, and size of atherogenic LDL particles (LDL&#x02010;p) and very low&#x02010;density lipoprotein particles (VLDL&#x02010;p) in circulation.<xref rid="jah32370-bib-0008" ref-type="ref">8</xref>, <xref rid="jah32370-bib-0009" ref-type="ref">9</xref> Accordingly, this study was designed (Figure&#x000a0;<xref rid="jah32370-fig-0001" ref-type="fig">1</xref>) to (1) identify potential NMR&#x02010;measured lipoproteins associated with incident CVD risk in a population of individuals with naturally normal or low LDL&#x02010;c, (2) understand the changes in the lipoprotein milieu accompanying high&#x02010;intensity statin therapy, and (3) identify lipoprotein subclasses associated with on&#x02010;statin risk of CVD events despite achieved low levels of LDL&#x02010;c. We sought to extend the findings by examining an independent, diverse cohort of individuals referred for cardiac catheterization (CATHGEN).</p><fig fig-type="Figure" xml:lang="en" id="jah32370-fig-0001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Overview of the study: impetus for the study, study populations, lipoprotein measures, lipoprotein profiling, and results. <styled-content style="fixed-case">CATHGEN</styled-content> indicates <styled-content style="fixed-case">CATH</styled-content>eterization <styled-content style="fixed-case">GEN</styled-content>etics biorepository; <styled-content style="fixed-case">CVD</styled-content>, cardiovascular disease; <styled-content style="fixed-case">JUPITER</styled-content>, Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin; <styled-content style="fixed-case">LDL</styled-content>, low&#x02010;density lipoproteins; LDL&#x02010;c, low&#x02010;density lipoprotein cholesterol; <styled-content style="fixed-case">NMR</styled-content>, nuclear magnetic resonance spectroscopy; <styled-content style="fixed-case">VLDL</styled-content>, very low&#x02010;density lipoproteins.</p></caption><graphic id="nlm-graphic-1" xlink:href="JAH3-6-e005549-g001"/></fig></sec><sec id="jah32370-sec-0010"><title>Material and Methods</title><sec id="jah32370-sec-0011"><title>Study Design and Population</title><p>The primary study population is derived from a primary&#x02010;prevention randomized controlled clinical trial of rosuvastatin 20&#x000a0;mg versus placebo (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin, JUPITER; NCT00239681).<xref rid="jah32370-bib-0010" ref-type="ref">10</xref> The JUPITER trial randomized individuals (women &#x02265;60&#x000a0;years, men &#x02265;50&#x000a0;years) without prior history of CVD or diabetes mellitus, all of whom had LDL&#x02010;c &#x0003c;130&#x000a0;mg/dL, high&#x02010;sensitivity C&#x02010;reactive protein (hsCRP &#x02265;2.0&#x000a0;mg/L), and triglycerides &#x02264;500&#x000a0;mg/dL. The relative risk reduction for the primary incident CVD end point was 44%.<xref rid="jah32370-bib-0010" ref-type="ref">10</xref>
</p><p>We performed <sup>1</sup>H NMR lipoprotein measurements on fasting blood samples from 11&#x000a0;984 participants (of whom 9222 also had 1&#x02010;year samples) who consented to and provided additional blood collection with sufficient plasma available. In the placebo&#x02010;allocated arm, baseline lipoprotein measurements were used to identify lipoproteins associated with risk of incident CVD in untreated individuals. In the statin&#x02010;allocated arm, (1) change in lipoprotein measurements from baseline to 12&#x000a0;months after randomization was used to understand the effects of statin therapy on lipoprotein subfractions, and (2) on&#x02010;statin (12&#x000a0;month) lipoprotein measurements were used to identify lipoproteins associated with residual on&#x02010;statin risk of incident CVD.</p></sec><sec id="jah32370-sec-0012"><title>Laboratory Analysis</title><p>Standard lipid measurements were performed on fasting samples by a central laboratory.<xref rid="jah32370-bib-0011" ref-type="ref">11</xref> LDL&#x02010;c was calculated by the Friedewald equation&#x000a0;(total cholesterol minus HDL&#x02010;c minus triglycerides/5) when triglycerides were &#x0003c;400&#x000a0;mg/dL, and measured by ultracentrifugation when triglycerides were &#x02265;400&#x000a0;mg/dL. Triglycerides were measured using a colorimetric assay. Measurement of apolipoproteins B (apoB) was via immunonephelometry by using a Behring nephelometric assay.<xref rid="jah32370-bib-0012" ref-type="ref">12</xref>
</p><p>After trial completion, <sup>1</sup>H NMR spectroscopy (400&#x000a0;MHz) LipoProfile III measurements were performed on stored plasma samples by LipoScience, Inc (Raleigh, NC; now LabCorp). NMR was used to quantify total LDL&#x02010;p and its lipoprotein subclass concentrations (small and large LDL&#x02010;p, and intermediate density lipoprotein [IDL&#x02010;p]), and average LDL particle size. Total VLDL&#x02010;p and its subclasses (small, medium, and large) were quantified, as well the concentration of VLDL and chylomicron triglyceride (VLDL/CM TG) and cholesterol (VLDL&#x02010;c). We also examined formulaic remnant cholesterol, which was calculated as total cholesterol minus HDL&#x02010;c minus LDL&#x02010;c. (Calculating remnant cholesterol as triglycerides divided by 5<xref rid="jah32370-bib-0013" ref-type="ref">13</xref> yielded nearly identical results, as expected, based on use of the Friedewald equation.)</p></sec><sec id="jah32370-sec-0013"><title>Outcomes</title><p>The primary outcome was the trial primary end point, a composite incident CVD end point defined as the occurrence of either myocardial infarction, stroke, hospitalization for unstable angina, arterial revascularization, or cardiovascular death.<xref rid="jah32370-bib-0010" ref-type="ref">10</xref> An expanded end point of CVD or all&#x02010;cause mortality was also examined, consistent with prior JUPITER biomarker analyses.<xref rid="jah32370-bib-0014" ref-type="ref">14</xref>
</p></sec><sec id="jah32370-sec-0014"><title>Extension to Other Populations</title><p>We sought to extend the JUPITER findings in an independent, prospective cohort encompassing a diverse population referred for cardiac catheterization at Duke University from 2001 to 2010 (CATHGEN; dmpi.duke.edu/cathgen).<xref rid="jah32370-bib-0015" ref-type="ref">15</xref> As in JUPITER, we focused on individuals with LDL&#x02010;c &#x0003c;130&#x000a0;mg/dL and TG &#x0003c;500&#x000a0;mg/dL (N=2149 individuals). (The hsCRP was not routinely measured.) We also examined the subset of participants with confirmed statin prescription (N=833) as well as, more broadly, risks among all comers in the cohort without LDL&#x02010;c stratification. Lipoprotein subclasses were measured using the same NMR assay as in JUPITER. Fatal or nonfatal myocardial infarction was the primary outcome in this mixed population of individuals both with and without established CVD. Cox models included all covariables used in the JUPITER analyses except for hsCRP, which was not routinely measured.</p></sec><sec id="jah32370-sec-0015"><title>Statistical Analyses</title><p>Medians (25th, 75th percentiles) were displayed for continuous variables. Lipoprotein change was evaluated using the Wilcoxon signed&#x02010;rank test. Exposure time was calculated as the time from randomization to end&#x02010;point occurrence or censoring (the latter including censoring at time of noncardiovascular mortality). Cox proportional hazards models were used to calculate hazard ratios and 95% CIs for CVD in relation to per&#x02010;SD increments in measures. Nonnormally distributed data were (natural) log transformed. Additionally, risk was examined across lipoprotein tertiles. Models were adjusted for age, sex, race, smoking, family history of premature coronary disease, body&#x02010;mass index, systolic blood pressure, fasting glucose, and hsCRP. Sensitivity analyses mutually adjusting for other NMR lipoprotein subclasses were performed,<xref rid="jah32370-bib-0016" ref-type="ref">16</xref> as well as adjusting for HDL&#x02010;c. Additionally, a minority of individuals in these analyses had events before on&#x02010;treatment NMR measurement; however, the majority of events occurred after measurement, and in sensitivity analyses beginning the follow&#x02010;up at time of NMR measurement, the results were not appreciably different, although with less power some associations were no longer significant. We assessed predictive model performance by assessing the change in Harrell C&#x02010;index (and quantitatively with the likelihood ratio test) for 2 hierarchically nested models predicting primary CVD events: (1) a model that incorporated all variables from the Cox model (above) plus standard lipids (LDL&#x02010;c, HDL&#x02010;c, and triglyceride), and (2) a full model including all variables from model 1 plus all of the atherogenic NMR lipoprotein measurements. Additionally, a more parsimonious model was selected through backwards elimination (retention threshold, <italic>P</italic>&#x0003c;0.10) starting with all variables in model 2; discrimination was assessed with Harrell C&#x02010;index, and the likelihood ratio test was used to determine if model 2 provided significantly improved discrimination over this parsimonious model. Analyses were performed using SAS version 9.3 (Cary, NC). A 2&#x02010;tailed <italic>P</italic>&#x0003c;0.05 was considered statistically significant. The study was approved by a local Institutional Review Board, and subjects provided informed consent.</p></sec></sec><sec id="jah32370-sec-0016"><title>Results</title><sec id="jah32370-sec-0017"><title>Baseline Characteristics</title><p>Study participants had a median (25th, 75th percentiles) age of 66 (60, 71) years, and were 36% female. Except for race/ethnicity, participants in the current study were generally representative of those in the original JUPITER trial (Table&#x000a0;<xref rid="jah32370-tbl-0001" ref-type="table-wrap">1</xref>).<xref rid="jah32370-bib-0010" ref-type="ref">10</xref> Median baseline LDL&#x02010;c was 109 (95, 120) mg/dL, triglycerides were 119 (87, 169) mg/dL, and hsCRP was 4.10 (2.75, 6.70) mg/L.</p><table-wrap id="jah32370-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label>Table 1</label><caption><p>Baseline Characteristics in the Study Sample Vs the Original JUPITER Cohort</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" valign="top" colspan="1">Characteristic</th><th align="left" style="border-bottom:solid 1px #000000" valign="top" rowspan="1" colspan="1">Current Study (N=11&#x000a0;984)</th><th align="left" style="border-bottom:solid 1px #000000" valign="top" rowspan="1" colspan="1">JUPITER (N=17&#x000a0;802)</th><th align="left" style="border-bottom:solid 1px #000000" valign="top" rowspan="1" colspan="1">Not in Current Study (N=5818)</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">Median (IQR) or N (%)</th><th align="left" valign="top" rowspan="1" colspan="1">Median (IQR) or N (%)</th><th align="left" valign="top" rowspan="1" colspan="1">Median (IQR) or N (%)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age</td><td align="left" rowspan="1" colspan="1">66 (60, 71)</td><td align="left" rowspan="1" colspan="1">66 (60, 71)</td><td align="left" rowspan="1" colspan="1">66 (61, 71)</td></tr><tr><td align="left" rowspan="1" colspan="1">Women</td><td align="left" rowspan="1" colspan="1">4360 (36)</td><td align="left" rowspan="1" colspan="1">6801 (38.2)</td><td align="left" rowspan="1" colspan="1">2411 (42)</td></tr><tr><td align="left" rowspan="1" colspan="1">Rosuvastatin</td><td align="left" rowspan="1" colspan="1">5934 (50)</td><td align="left" rowspan="1" colspan="1">8901 (50.0)</td><td align="left" rowspan="1" colspan="1">2967 (51)</td></tr><tr><td align="left" colspan="4" rowspan="1">Race/ethnicity</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">White</td><td align="left" rowspan="1" colspan="1">9894 (82.6)</td><td align="left" rowspan="1" colspan="1">12&#x000a0;683 (71.3)</td><td align="left" rowspan="1" colspan="1">2789 (48)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Black</td><td align="left" rowspan="1" colspan="1">746 (6.2)</td><td align="left" rowspan="1" colspan="1">2224 (12.5)</td><td align="left" rowspan="1" colspan="1">1478 (25)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Asian</td><td align="left" rowspan="1" colspan="1">178 (1.5)</td><td align="left" rowspan="1" colspan="1">283 (1.6)</td><td align="left" rowspan="1" colspan="1">105 (1.8)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Hispanic</td><td align="left" rowspan="1" colspan="1">1076 (9.0)</td><td align="left" rowspan="1" colspan="1">2261 (12.7)</td><td align="left" rowspan="1" colspan="1">1185 (20)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Other/unknown</td><td align="left" rowspan="1" colspan="1">88 (0.7)</td><td align="left" rowspan="1" colspan="1">349 (2.0)</td><td align="left" rowspan="1" colspan="1">261 (5)</td></tr><tr><td align="left" rowspan="1" colspan="1">Body&#x02010;mass index, kg/m<sup>2</sup>
</td><td align="left" rowspan="1" colspan="1">28.4 (25.5, 32.0)</td><td align="left" rowspan="1" colspan="1">28.4 (25.3, 32.0)</td><td align="left" rowspan="1" colspan="1">28.0 (24.7, 32.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">Hypertension, %</td><td align="left" rowspan="1" colspan="1">6719 (56.1)</td><td align="left" rowspan="1" colspan="1">10&#x000a0;208 (57)</td><td align="left" rowspan="1" colspan="1">3489 (60)</td></tr><tr><td align="left" rowspan="1" colspan="1">Systolic blood pressure, mm&#x000a0;Hg</td><td align="left" rowspan="1" colspan="1">134 (124, 146)</td><td align="left" rowspan="1" colspan="1">134 (124, 145)</td><td align="left" rowspan="1" colspan="1">134 (125, 145)</td></tr><tr><td align="left" rowspan="1" colspan="1">Diastolic blood pressure, mm&#x000a0;Hg</td><td align="left" rowspan="1" colspan="1">80 (75, 86)</td><td align="left" rowspan="1" colspan="1">80 (75, 87)</td><td align="left" rowspan="1" colspan="1">80 (76, 88)</td></tr><tr><td align="left" rowspan="1" colspan="1">Current smoker</td><td align="left" rowspan="1" colspan="1">1757 (14.7)</td><td align="left" rowspan="1" colspan="1">2820 (15.9)</td><td align="left" rowspan="1" colspan="1">1063 (18)</td></tr><tr><td align="left" rowspan="1" colspan="1">Family history of premature CAD</td><td align="left" rowspan="1" colspan="1">1527 (12.8)</td><td align="left" rowspan="1" colspan="1">2045 (11.5)</td><td align="left" rowspan="1" colspan="1">518 (9.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">Glucose, mg/dL</td><td align="left" rowspan="1" colspan="1">95 (88, 102)</td><td align="left" rowspan="1" colspan="1">94 (88, 102)</td><td align="left" rowspan="1" colspan="1">93 (86, 101)</td></tr><tr><td align="left" rowspan="1" colspan="1">hsCRP, mg/L</td><td align="left" rowspan="1" colspan="1">4.10 (2.75, 6.70)</td><td align="left" rowspan="1" colspan="1">4.25 (2.85, 7.10)</td><td align="left" rowspan="1" colspan="1">4.70 (2.95, 8.05)</td></tr><tr><td align="left" rowspan="1" colspan="1">LDL cholesterol, mg/dL</td><td align="left" rowspan="1" colspan="1">109 (95, 119.5)</td><td align="left" rowspan="1" colspan="1">108 (94, 119)</td><td align="left" rowspan="1" colspan="1">106 (91, 118)</td></tr><tr><td align="left" rowspan="1" colspan="1">Non&#x02010;HDL cholesterol, mg/dL</td><td align="left" rowspan="1" colspan="1">135 (120, 147)</td><td align="left" rowspan="1" colspan="1">134 (118, 147)</td><td align="left" rowspan="1" colspan="1">132 (114, 146)</td></tr><tr><td align="left" rowspan="1" colspan="1">Apolipoprotein B, mg/dL</td><td align="left" rowspan="1" colspan="1">109 (97, 122)</td><td align="left" rowspan="1" colspan="1">109 (95, 122)</td><td align="left" rowspan="1" colspan="1">108 (93, 122)</td></tr><tr><td align="left" rowspan="1" colspan="1">Triglycerides, mg/dL</td><td align="left" rowspan="1" colspan="1">119 (87, 169)</td><td align="left" rowspan="1" colspan="1">118 (85, 169)</td><td align="left" rowspan="1" colspan="1">116 (83, 169)</td></tr><tr><td align="left" rowspan="1" colspan="1">HDL cholesterol, mg/dL</td><td align="left" rowspan="1" colspan="1">49 (41, 60)</td><td align="left" rowspan="1" colspan="1">49 (40, 60)</td><td align="left" rowspan="1" colspan="1">48 (40, 59)</td></tr></tbody></table><table-wrap-foot><fn id="jah32370-note-0001"><p>CAD indicates coronary artery disease; hsCRP, high&#x02010;sensitivity C&#x02010;reactive protein; IQR, interquartile range; JUPITER, Justification for the Use of Statins in Prevention: an Intervention Trial; LDL&#x02010;c, low&#x02010;density lipoprotein cholesterol; LDL&#x02010;p, low density lipoprotein particle concentration; non&#x02010;HDL&#x02010;c, non&#x02010;high&#x02010;density lipoprotein cholesterol concentration; VLDL&#x02010;c, very low density lipoprotein cholesterol; VLDL&#x02010;p, very low density lipoprotein particle concentration.</p></fn></table-wrap-foot></table-wrap><p>Total LDL&#x02010;p and apoB were strongly correlated at baseline (Table&#x000a0;<xref rid="jah32370-tbl-0002" ref-type="table-wrap">2</xref>), and LDL&#x02010;p was the most abundant atherogenic lipoprotein (Figure&#x000a0;<xref rid="jah32370-fig-0002" ref-type="fig">2</xref>; Table&#x000a0;<xref rid="jah32370-tbl-0003" ref-type="table-wrap">3</xref>). NMR&#x02010;measured VLDL/CM triglyceride was strongly correlated with chemically measured triglycerides and with large VLDL&#x02010;p (and progressively less with medium and small VLDL&#x02010;p). Calculated remnant cholesterol was (as expected based on the use of the Friedewald equation) perfectly correlated with triglyceride (<italic>r</italic>=1.00), moderately with apoB, non&#x02010;HDL&#x02010;c, and VLDL&#x02010;c (<italic>r</italic>=0.48, 0.60, and 0.58, respectively), and not with LDL&#x02010;c (<italic>r</italic>=0.01).</p><table-wrap id="jah32370-tbl-0002" xml:lang="en" orientation="portrait" position="float"><label>Table 2</label><caption><p>Spearman Correlations Between Lipid and Lipoprotein Markers at Baseline (N=11&#x000a0;984)</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" valign="top" colspan="1"/><th align="left" rowspan="2" valign="top" colspan="1">LDL&#x02010;c</th><th align="left" rowspan="2" valign="top" colspan="1">Non&#x02010;HDL&#x02010;c</th><th align="left" rowspan="2" valign="top" colspan="1">ApoB</th><th align="left" rowspan="2" valign="top" colspan="1">Triglycerides</th><th align="left" rowspan="2" valign="top" colspan="1">RC</th><th align="left" rowspan="2" valign="top" colspan="1">HDL&#x02010;c</th><th align="left" rowspan="2" valign="top" colspan="1">LDL Size</th><th align="left" colspan="4" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">LDL&#x02010;p</th><th align="left" rowspan="2" valign="top" colspan="1">VLDL Size</th><th align="left" colspan="4" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">VLDL&#x02010;p</th><th align="left" rowspan="2" valign="top" colspan="1">VLDLc</th><th align="left" rowspan="2" valign="top" colspan="1">VLDL/CM Triglycerides</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">Total</th><th align="left" valign="top" rowspan="1" colspan="1">Large</th><th align="left" valign="top" rowspan="1" colspan="1">Small</th><th align="left" valign="top" rowspan="1" colspan="1">IDL</th><th align="left" valign="top" rowspan="1" colspan="1">Total</th><th align="left" valign="top" rowspan="1" colspan="1">Large</th><th align="left" valign="top" rowspan="1" colspan="1">Medium</th><th align="left" valign="top" rowspan="1" colspan="1">Small</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">LDL&#x02010;c</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">0.75</td><td align="left" rowspan="1" colspan="1">0.51</td><td align="left" rowspan="1" colspan="1">0.01</td><td align="left" rowspan="1" colspan="1">0.01</td><td align="left" rowspan="1" colspan="1">0.05</td><td align="left" rowspan="1" colspan="1">0.15</td><td align="left" rowspan="1" colspan="1">0.40</td><td align="left" rowspan="1" colspan="1">0.33</td><td align="left" rowspan="1" colspan="1">0.09</td><td align="left" rowspan="1" colspan="1">0.19</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;0.11</td><td align="left" rowspan="1" colspan="1">0.12</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;0.01</td><td align="left" rowspan="1" colspan="1">0.06</td><td align="left" rowspan="1" colspan="1">0.13</td><td align="left" rowspan="1" colspan="1">0.58</td><td align="left" rowspan="1" colspan="1">0.05</td></tr><tr><td align="left" rowspan="1" colspan="1">Non&#x02010;HDL&#x02010;c</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">0.71</td><td align="left" rowspan="1" colspan="1">0.60</td><td align="left" rowspan="1" colspan="1">0.60</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;0.27</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;0.21</td><td align="left" rowspan="1" colspan="1">0.61</td><td align="left" rowspan="1" colspan="1">0.03</td><td align="left" rowspan="1" colspan="1">0.44</td><td align="left" rowspan="1" colspan="1">0.16</td><td align="left" rowspan="1" colspan="1">0.18</td><td align="left" rowspan="1" colspan="1">0.42</td><td align="left" rowspan="1" colspan="1">0.39</td><td align="left" rowspan="1" colspan="1">0.38</td><td align="left" rowspan="1" colspan="1">0.27</td><td align="left" rowspan="1" colspan="1">0.45</td><td align="left" rowspan="1" colspan="1">0.46</td></tr><tr><td align="left" rowspan="1" colspan="1">ApoB</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">0.48</td><td align="left" rowspan="1" colspan="1">0.48</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;0.29</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;0.21</td><td align="left" rowspan="1" colspan="1">0.79</td><td align="left" rowspan="1" colspan="1">0.13</td><td align="left" rowspan="1" colspan="1">0.53</td><td align="left" rowspan="1" colspan="1">0.18</td><td align="left" rowspan="1" colspan="1">0.16</td><td align="left" rowspan="1" colspan="1">0.39</td><td align="left" rowspan="1" colspan="1">0.36</td><td align="left" rowspan="1" colspan="1">0.37</td><td align="left" rowspan="1" colspan="1">0.23</td><td align="left" rowspan="1" colspan="1">0.42</td><td align="left" rowspan="1" colspan="1">0.43</td></tr><tr><td align="left" rowspan="1" colspan="1">Triglycerides</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;0.49</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;0.49</td><td align="left" rowspan="1" colspan="1">0.47</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;0.32</td><td align="left" rowspan="1" colspan="1">0.59</td><td align="left" rowspan="1" colspan="1">0.04</td><td align="left" rowspan="1" colspan="1">0.42</td><td align="left" rowspan="1" colspan="1">0.52</td><td align="left" rowspan="1" colspan="1">0.64</td><td align="left" rowspan="1" colspan="1">0.53</td><td align="left" rowspan="1" colspan="1">0.28</td><td align="left" rowspan="1" colspan="1">0.58</td><td align="left" rowspan="1" colspan="1">0.69</td></tr><tr><td align="left" rowspan="1" colspan="1">RC</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;0.49</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;0.49</td><td align="left" rowspan="1" colspan="1">0.46</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;0.32</td><td align="left" rowspan="1" colspan="1">0.59</td><td align="left" rowspan="1" colspan="1">0.41</td><td align="left" rowspan="1" colspan="1">0.42</td><td align="left" rowspan="1" colspan="1">0.52</td><td align="left" rowspan="1" colspan="1">0.63</td><td align="left" rowspan="1" colspan="1">0.53</td><td align="left" rowspan="1" colspan="1">0.28</td><td align="left" rowspan="1" colspan="1">0.58</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">HDL&#x02010;c</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">0.57</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;0.38</td><td align="left" rowspan="1" colspan="1">0.35</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;0.60</td><td align="left" rowspan="1" colspan="1">0.16</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;0.16</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;0.38</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;0.35</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;0.38</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;0.22</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;0.40</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;0.42</td></tr><tr><td align="left" rowspan="1" colspan="1">LDL size</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;0.32</td><td align="left" rowspan="1" colspan="1">0.70</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;0.77</td><td align="left" rowspan="1" colspan="1">0.10</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;0.26</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;0.39</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;0.42</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;0.42</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;0.19</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;0.43</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;0.49</td></tr><tr><td align="left" rowspan="1" colspan="1">LDL&#x02010;p</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Total</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">0.17</td><td align="left" rowspan="1" colspan="1">0.71</td><td align="left" rowspan="1" colspan="1">0.09</td><td align="left" rowspan="1" colspan="1">0.18</td><td align="left" rowspan="1" colspan="1">0.29</td><td align="left" rowspan="1" colspan="1">0.31</td><td align="left" rowspan="1" colspan="1">0.34</td><td align="left" rowspan="1" colspan="1">0.13</td><td align="left" rowspan="1" colspan="1">0.33</td><td align="left" rowspan="1" colspan="1">0.37</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Large</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;0.45</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;0.05</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;0.38</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;0.24</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;0.41</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;0.31</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;0.05</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;0.28</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;0.39</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Small</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;0.14</td><td align="left" rowspan="1" colspan="1">0.33</td><td align="left" rowspan="1" colspan="1">0.41</td><td align="left" rowspan="1" colspan="1">0.50</td><td align="left" rowspan="1" colspan="1">0.47</td><td align="left" rowspan="1" colspan="1">0.18</td><td align="left" rowspan="1" colspan="1">0.48</td><td align="left" rowspan="1" colspan="1">0.55</td></tr><tr><td align="left" rowspan="1" colspan="1">IDL&#x02010;p</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">0.17</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;0.03</td><td align="left" rowspan="1" colspan="1">0.09</td><td align="left" rowspan="1" colspan="1">0.14</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;0.13</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;0.04</td><td align="left" rowspan="1" colspan="1">0.07</td></tr><tr><td align="left" rowspan="1" colspan="1">VLDL size</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">0.03</td><td align="left" rowspan="1" colspan="1">0.76</td><td align="left" rowspan="1" colspan="1">0.35</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;0.30</td><td align="left" rowspan="1" colspan="1">0.13</td><td align="left" rowspan="1" colspan="1">0.51</td></tr><tr><td align="left" rowspan="1" colspan="1">VLDL&#x02010;p</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Total</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">0.56</td><td align="left" rowspan="1" colspan="1">0.66</td><td align="left" rowspan="1" colspan="1">0.85</td><td align="left" rowspan="1" colspan="1">0.98</td><td align="left" rowspan="1" colspan="1">0.84</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Large</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">0.58</td><td align="left" rowspan="1" colspan="1">0.24</td><td align="left" rowspan="1" colspan="1">0.70</td><td align="left" rowspan="1" colspan="1">0.87</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Medium</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">0.22</td><td align="left" rowspan="1" colspan="1">0.66</td><td align="left" rowspan="1" colspan="1">0.79</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Small</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">0.79</td><td align="left" rowspan="1" colspan="1">0.50</td></tr><tr><td align="left" rowspan="1" colspan="1">VLDL&#x02010;c</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">0.89</td></tr><tr><td align="left" rowspan="1" colspan="1">VLDL/CM triglycerides</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td><td align="left" rowspan="1" colspan="1">&#x000b7;&#x000b7;&#x000b7;</td></tr></tbody></table><table-wrap-foot><fn id="jah32370-note-0002"><p>All <italic>P</italic> values for Spearman correlations were &#x0003c;0.0001 except for the Spearman <italic>r</italic> of LDL&#x02010;c and triglycerides (<italic>P</italic>=0.175), LDL&#x02010;c and VLDL&#x02010;p<sub>large</sub> (<italic>P</italic>=0.514), LDL&#x02010;c and RC (<italic>P</italic>=0.1813), non&#x02010;HDL&#x02010;c and LDL&#x02010;p<sub>large</sub> (<italic>P</italic>=0.001), VLDL&#x02010;p<sub>total</sub> and IDL&#x02010;p (<italic>P</italic>=0.0003), and VLDL&#x02010;p<sub>total</sub> and VLDL size (<italic>P</italic>=0.0002). ApoB indicates apolipoprotein b; CM, chylomicrons; LDL&#x02010;c, low&#x02010;density lipoprotein cholesterol; LDL&#x02010;p, low&#x02010;density lipoprotein particle concentration; non&#x02010;HDL&#x02010;c, non&#x02010;high&#x02010;density lipoprotein cholesterol concentration; RC, remnant cholesterol; VLDL&#x02010;c, very low&#x02010;density lipoprotein cholesterol; VLDL&#x02010;p, very low&#x02010;density lipoprotein particle concentration.</p></fn></table-wrap-foot></table-wrap><fig fig-type="Figure" xml:lang="en" id="jah32370-fig-0002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Schematic representation of the median proportion of atherogenic (<styled-content style="fixed-case">LDL</styled-content> and <styled-content style="fixed-case">VLDL</styled-content>) lipoprotein subclasses (median subclass particle concentration divided by median total <styled-content style="fixed-case">LDL</styled-content>+<styled-content style="fixed-case">VLDL</styled-content> particle concentration measured with <styled-content style="fixed-case">NMR</styled-content>) at baseline in fasting samples in the rosuvastatin arm pre&#x02010;treatment. <styled-content style="fixed-case">IDL</styled-content>&#x02010;p indicates intermediate density lipoprotein particle concentration; <styled-content style="fixed-case">LDL</styled-content>&#x02010;p, low density lipoprotein particle concentration; NMR, nuclear magnetic resonance; VLDL&#x02010;p, very low density lipoprotein particle concentration.</p></caption><graphic id="nlm-graphic-3" xlink:href="JAH3-6-e005549-g002"/></fig><table-wrap id="jah32370-tbl-0003" xml:lang="en" orientation="portrait" position="float"><label>Table 3</label><caption><p>Baseline, Follow&#x02010;Up, and Change in Lipid and Lipoprotein Measures in the Placebo and Rosuvastatin Groups<xref ref-type="fn" rid="jah32370-note-0004">a</xref>
</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1"/><th align="left" valign="top" rowspan="1" colspan="1">Baseline</th><th align="left" valign="top" rowspan="1" colspan="1">Year 1<xref ref-type="fn" rid="jah32370-note-0005">b</xref>
</th><th align="left" valign="top" rowspan="1" colspan="1">Absolute Change<xref ref-type="fn" rid="jah32370-note-0006">c</xref>
</th><th align="left" valign="top" rowspan="1" colspan="1">% Change</th></tr></thead><tbody><tr><td align="left" colspan="5" rowspan="1">Lipids and apolipoproteins, mg/dL</td></tr><tr><td align="left" style="padding-left:10%" colspan="5" rowspan="1">LDL&#x02010;c</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Placebo</td><td align="left" rowspan="1" colspan="1">110 (96, 119)</td><td align="left" rowspan="1" colspan="1">111 (96, 125)</td><td align="left" rowspan="1" colspan="1">3 (&#x02212;8, 15)</td><td align="left" rowspan="1" colspan="1">2.7 (&#x02212;7.4, 14.4)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Rosuvastatin</td><td align="left" rowspan="1" colspan="1">109 (96, 120)</td><td align="left" rowspan="1" colspan="1">55 (44, 71)</td><td align="left" rowspan="1" colspan="1">&#x02212;51 (&#x02212;65, &#x02212;31)</td><td align="left" rowspan="1" colspan="1">&#x02212;49.0 (&#x02212;58.2, &#x02212;32.8)</td></tr><tr><td align="left" style="padding-left:10%" colspan="5" rowspan="1">Non&#x02010;HDL&#x02010;c</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Placebo</td><td align="left" rowspan="1" colspan="1">135 (121, 147)</td><td align="left" rowspan="1" colspan="1">138 (121, 154)</td><td align="left" rowspan="1" colspan="1">3 (&#x02212;9, 16)</td><td align="left" rowspan="1" colspan="1">2.4 (&#x02212;6.4, 12.1)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Rosuvastatin</td><td align="left" rowspan="1" colspan="1">135 (121, 148)</td><td align="left" rowspan="1" colspan="1">77 (65, 96)</td><td align="left" rowspan="1" colspan="1">&#x02212;56 (&#x02212;71, &#x02212;34)</td><td align="left" rowspan="1" colspan="1">&#x02212;42.7 (&#x02212;51.1, &#x02212;27.7)</td></tr><tr><td align="left" style="padding-left:10%" colspan="5" rowspan="1">Apolipoprotein B</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Placebo</td><td align="left" rowspan="1" colspan="1">110 (97, 122)</td><td align="left" rowspan="1" colspan="1">106 (93, 119)</td><td align="left" rowspan="1" colspan="1">&#x02212;3 (&#x02212;13, 7)</td><td align="left" rowspan="1" colspan="1">&#x02212;2.9 (&#x02212;11.6, 6.3)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Rosuvastatin</td><td align="left" rowspan="1" colspan="1">110 (97, 123)</td><td align="left" rowspan="1" colspan="1">66 (57, 81)</td><td align="left" rowspan="1" colspan="1">&#x02212;42 (&#x02212;54, &#x02212;27)</td><td align="left" rowspan="1" colspan="1">&#x02212;39.4 (&#x02212;47.6, &#x02212;26.7)</td></tr><tr><td align="left" style="padding-left:10%" colspan="5" rowspan="1">Triglycerides</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Placebo</td><td align="left" rowspan="1" colspan="1">119 (88, 168)</td><td align="left" rowspan="1" colspan="1">120 (90, 167)</td><td align="left" rowspan="1" colspan="1">2 (&#x02212;24, 25)</td><td align="left" rowspan="1" colspan="1">1.3 (&#x02212;18.4, 24.7)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Rosuvastatin</td><td align="left" rowspan="1" colspan="1">120 (88, 171)</td><td align="left" rowspan="1" colspan="1">102 (77, 139)</td><td align="left" rowspan="1" colspan="1">&#x02212;17 (&#x02212;48, 5)</td><td align="left" rowspan="1" colspan="1">&#x02212;15.5 (&#x02212;32.8, 5.26)</td></tr><tr><td align="left" colspan="5" rowspan="1">NMR lipoproteins</td></tr><tr><td align="left" style="padding-left:10%" colspan="5" rowspan="1">LDL size, nm diameter</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Placebo</td><td align="left" rowspan="1" colspan="1">21 (20.5, 21.4)</td><td align="left" rowspan="1" colspan="1">21 (20.5, 21.3)</td><td align="left" rowspan="1" colspan="1">0.0 (&#x02212;0.3, 0.3)</td><td align="left" rowspan="1" colspan="1">0.0 (&#x02212;1.5, 1.4)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Rosuvastatin</td><td align="left" rowspan="1" colspan="1">21 (20.5, 21.4)</td><td align="left" rowspan="1" colspan="1">20.6 (20.2, 21.0)</td><td align="left" rowspan="1" colspan="1">&#x02212;0.3 (&#x02212;0.8, 0.1)</td><td align="left" rowspan="1" colspan="1">&#x02212;1.5 (&#x02212;3.7, 0.5)</td></tr><tr><td align="left" style="padding-left:10%" colspan="5" rowspan="1">LDL&#x02010;p by subclass, nmol/L</td></tr><tr><td align="left" style="padding-left:15%" colspan="5" rowspan="1">Total</td></tr><tr><td align="left" style="padding-left:20%" rowspan="1" colspan="1">Placebo</td><td align="left" rowspan="1" colspan="1">1282 (1089, 1476)</td><td align="left" rowspan="1" colspan="1">1224 (1044, 1427)</td><td align="left" rowspan="1" colspan="1">&#x02212;52 (&#x02212;197, 95)</td><td align="left" rowspan="1" colspan="1">&#x02212;4.2 (14.7, 8.3)</td></tr><tr><td align="left" style="padding-left:20%" rowspan="1" colspan="1">Rosuvastatin</td><td align="left" rowspan="1" colspan="1">1274 (1101, 1484)</td><td align="left" rowspan="1" colspan="1">771 (633, 964)</td><td align="left" rowspan="1" colspan="1">&#x02212;487 (&#x02212;674, &#x02212;284)</td><td align="left" rowspan="1" colspan="1">&#x02212;39.6 (&#x02212;49.4, &#x02212;24.7)</td></tr><tr><td align="left" style="padding-left:15%" colspan="5" rowspan="1">Large</td></tr><tr><td align="left" style="padding-left:20%" rowspan="1" colspan="1">Placebo</td><td align="left" rowspan="1" colspan="1">457 (307, 602)</td><td align="left" rowspan="1" colspan="1">438 (276, 586)</td><td align="left" rowspan="1" colspan="1">&#x02212;20 (&#x02212;143, 104)</td><td align="left" rowspan="1" colspan="1">&#x02212;5.3 (&#x02212;31.0, 27.4)</td></tr><tr><td align="left" style="padding-left:20%" rowspan="1" colspan="1">Rosuvastatin</td><td align="left" rowspan="1" colspan="1">462 (304, 600)</td><td align="left" rowspan="1" colspan="1">174 (93, 306)</td><td align="left" rowspan="1" colspan="1">&#x02212;237 (&#x02212;391, &#x02212;71)</td><td align="left" rowspan="1" colspan="1">&#x02212;57.5 (&#x02212;77, &#x02212;24.4)</td></tr><tr><td align="left" style="padding-left:15%" colspan="5" rowspan="1">Small</td></tr><tr><td align="left" style="padding-left:20%" rowspan="1" colspan="1">Placebo</td><td align="left" rowspan="1" colspan="1">612 (448, 841)</td><td align="left" rowspan="1" colspan="1">596 (440, 829)</td><td align="left" rowspan="1" colspan="1">&#x02212;14 (&#x02212;159, 127)</td><td align="left" rowspan="1" colspan="1">&#x02212;2.6 (&#x02212;22.9, 23.2)</td></tr><tr><td align="left" style="padding-left:20%" rowspan="1" colspan="1">Rosuvastatin</td><td align="left" rowspan="1" colspan="1">608 (446, 849)</td><td align="left" rowspan="1" colspan="1">494 (374, 624)</td><td align="left" rowspan="1" colspan="1">&#x02212;127 (&#x02212;320, 19)</td><td align="left" rowspan="1" colspan="1">&#x02212;22.1 (&#x02212;42.8, 4.5)</td></tr><tr><td align="left" style="padding-left:15%" colspan="5" rowspan="1">IDL&#x02010;p total, nmol/L</td></tr><tr><td align="left" style="padding-left:20%" rowspan="1" colspan="1">Placebo</td><td align="left" rowspan="1" colspan="1">151 (96, 220)</td><td align="left" rowspan="1" colspan="1">139 (85, 201)</td><td align="left" rowspan="1" colspan="1">&#x02212;14 (&#x02212;82, 56)</td><td align="left" rowspan="1" colspan="1">&#x02212;10.6 (&#x02212;45.3, 49.0)</td></tr><tr><td align="left" style="padding-left:20%" rowspan="1" colspan="1">Rosuvastatin</td><td align="left" rowspan="1" colspan="1">156 (99, 225)</td><td align="left" rowspan="1" colspan="1">83 (52, 124)</td><td align="left" rowspan="1" colspan="1">&#x02212;68 (&#x02212;138, &#x02212;4)</td><td align="left" rowspan="1" colspan="1">&#x02212;45.9 (&#x02212;69.4, &#x02212;4.4)</td></tr><tr><td align="left" style="padding-left:10%" colspan="5" rowspan="1">VLDL size, nm diameter</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Placebo</td><td align="left" rowspan="1" colspan="1">49 (44.3, 53.7)</td><td align="left" rowspan="1" colspan="1">49.3 (44.6, 55.0)</td><td align="left" rowspan="1" colspan="1">0.6 (&#x02212;3.7, 5.0)</td><td align="left" rowspan="1" colspan="1">1.3 (&#x02212;7.3, 10.9)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Rosuvastatin</td><td align="left" rowspan="1" colspan="1">49 (44.3, 54.1)</td><td align="left" rowspan="1" colspan="1">50.2 (46.1, 55.1)</td><td align="left" rowspan="1" colspan="1">1.4 (&#x02212;3.0, 5.9)</td><td align="left" rowspan="1" colspan="1">2.9 (&#x02212;5.8, 12.7)</td></tr><tr><td align="left" style="padding-left:10%" colspan="5" rowspan="1">VLDL&#x02010;p by subclass, nmol/L</td></tr><tr><td align="left" style="padding-left:15%" colspan="5" rowspan="1">Total</td></tr><tr><td align="left" style="padding-left:20%" rowspan="1" colspan="1">Placebo</td><td align="left" rowspan="1" colspan="1">43.8 (30.1, 58.5)</td><td align="left" rowspan="1" colspan="1">44.1 (30.9, 60.8)</td><td align="left" rowspan="1" colspan="1">1.2 (&#x02212;10.1, 13)</td><td align="left" rowspan="1" colspan="1">3.5 (&#x02212;21.8, 35.4)</td></tr><tr><td align="left" style="padding-left:20%" rowspan="1" colspan="1">Rosuvastatin</td><td align="left" rowspan="1" colspan="1">43.3 (29.9, 58.8)</td><td align="left" rowspan="1" colspan="1">33.8 (23.5, 46.7)</td><td align="left" rowspan="1" colspan="1">&#x02212;8.5 (&#x02212;20.4, 3.2)</td><td align="left" rowspan="1" colspan="1">&#x02212;19.6 (&#x02212;40.5, 10.2)</td></tr><tr><td align="left" style="padding-left:15%" colspan="5" rowspan="1">Large</td></tr><tr><td align="left" style="padding-left:20%" rowspan="1" colspan="1">Placebo</td><td align="left" rowspan="1" colspan="1">2.8 (1.3, 4.9)</td><td align="left" rowspan="1" colspan="1">3.0 (1.3, 5.6)</td><td align="left" rowspan="1" colspan="1">0.2 (&#x02212;1.0, 1.6)</td><td align="left" rowspan="1" colspan="1">7.7 (&#x02212;35.7, 75.9)</td></tr><tr><td align="left" style="padding-left:20%" rowspan="1" colspan="1">Rosuvastatin</td><td align="left" rowspan="1" colspan="1">2.8 (1.4, 5.0)</td><td align="left" rowspan="1" colspan="1">2.2 (1.1, 4.2)</td><td align="left" rowspan="1" colspan="1">&#x02212;0.3 (&#x02212;1.7, 0.7)</td><td align="left" rowspan="1" colspan="1">&#x02212;15.4 (&#x02212;50.0, 40.0)</td></tr><tr><td align="left" style="padding-left:15%" colspan="5" rowspan="1">Medium</td></tr><tr><td align="left" style="padding-left:20%" rowspan="1" colspan="1">Placebo</td><td align="left" rowspan="1" colspan="1">11.8 (6.8, 18.7)</td><td align="left" rowspan="1" colspan="1">13.6 (7.6, 22.4)</td><td align="left" rowspan="1" colspan="1">1.9 (&#x02212;3.2, 8.0)</td><td align="left" rowspan="1" colspan="1">16.7 (&#x02212;26.7, 86.7)</td></tr><tr><td align="left" style="padding-left:20%" rowspan="1" colspan="1">Rosuvastatin</td><td align="left" rowspan="1" colspan="1">11.6 (6.8, 18.6)</td><td align="left" rowspan="1" colspan="1">10.9 (6.5, 17.1)</td><td align="left" rowspan="1" colspan="1">&#x02212;0.6 (&#x02212;6.0, 4.4)</td><td align="left" rowspan="1" colspan="1">&#x02212;7.0 (&#x02212;42.9, 52.0)</td></tr><tr><td align="left" style="padding-left:15%" colspan="5" rowspan="1">Small</td></tr><tr><td align="left" style="padding-left:20%" rowspan="1" colspan="1">Placebo</td><td align="left" rowspan="1" colspan="1">27.1 (17.3, 38.1)</td><td align="left" rowspan="1" colspan="1">25 (16.3, 36.4)</td><td align="left" rowspan="1" colspan="1">&#x02212;1.4 (&#x02212;12.0, 9.3)</td><td align="left" rowspan="1" colspan="1">&#x02212;6.0 (&#x02212;37.8, 43.5)</td></tr><tr><td align="left" style="padding-left:20%" rowspan="1" colspan="1">Rosuvastatin</td><td align="left" rowspan="1" colspan="1">26.6 (17, 38.5)</td><td align="left" rowspan="1" colspan="1">19.4 (12.4, 28.0)</td><td align="left" rowspan="1" colspan="1">&#x02212;6.9 (&#x02212;17.3, 3.0)</td><td align="left" rowspan="1" colspan="1">&#x02212;26.8 (&#x02212;53.2, 16.4)</td></tr><tr><td align="left" style="padding-left:10%" colspan="5" rowspan="1">VLDL triglycerides, mg/dL</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Placebo</td><td align="left" rowspan="1" colspan="1">62.3 (42.7, 87.7)</td><td align="left" rowspan="1" colspan="1">64 (44.2, 94.1)</td><td align="left" rowspan="1" colspan="1">3.1 (&#x02212;12.1, 20.2)</td><td align="left" rowspan="1" colspan="1">5.6 (&#x02212;18.8, 35.8)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Rosuvastatin</td><td align="left" rowspan="1" colspan="1">62.3 (43.5, 88.3)</td><td align="left" rowspan="1" colspan="1">51.6 (36.5, 74.6)</td><td align="left" rowspan="1" colspan="1">&#x02212;9.0 (&#x02212;25.9, 5.5)</td><td align="left" rowspan="1" colspan="1">&#x02212;15.2 (&#x02212;35.8, 11.3)</td></tr></tbody></table><table-wrap-foot><fn id="jah32370-note-0003"><p>Values obtained from individuals with both baseline and year 1 measurements (n=9222). HDL indicates high&#x02010;density lipoproteins; IDL, intermediate&#x02010;density lipoproteins; LDL&#x02010;c, low&#x02010;density lipoprotein cholesterol; LDL&#x02010;p, low&#x02010;density lipoprotein particle concentration; non&#x02010;HDL&#x02010;c, non&#x02010;high&#x02010;density lipoprotein cholesterol concentration; NMR, nuclear magnetic resonance; RC, remnant cholesterol; VLDL&#x02010;c, very low&#x02010;density lipoprotein cholesterol; VLDL&#x02010;p, very low&#x02010;density lipoprotein particle concentration.</p></fn><fn id="jah32370-note-0004"><label>a</label><p>Median (25th percentile, 75th percentile).</p></fn><fn id="jah32370-note-0005"><label>b</label><p>
<italic>P</italic> values from the Wilcoxon signed&#x02010;rank test comparing baseline and year&#x02010;1 values were statistically significant (<italic>P</italic>&#x0003c;0.001) for all, with the exception of triglycerides among the placebo group (<italic>P</italic>=0.15).</p></fn><fn id="jah32370-note-0006"><label>c</label><p>
<italic>P</italic> values from the Wilcoxon rank&#x02010;sum test comparing the change among the rosuvastatin group with the change among the placebo group were &#x0003c;0.001 for all.</p></fn></table-wrap-foot></table-wrap></sec><sec id="jah32370-sec-0018"><title>Baseline Risk of Incident CVD</title><p>Among the 11&#x000a0;984 JUPITER participants, a total of 296 primary events and 489 expanded end points occurred over a median follow&#x02010;up of 2.0 (maximum 5.0) years, representing 27&#x000a0;864&#x000a0;person&#x02010;years. Among participants in the placebo&#x02010;allocated arm (N=6050; 189 events; Figure&#x000a0;<xref rid="jah32370-fig-0003" ref-type="fig">3</xref>), LDL&#x02010;c was not associated with increased risk of the primary end point, but significant associations were observed for non&#x02010;HDL&#x02010;c (1.17 [1.01, 1.36]), triglycerides (1.28 [1.10, 1.48]), and apoB (1.27 [1.09, 1.47]). For the expanded end point that included all&#x02010;cause mortality (291 events; Table&#x000a0;<xref rid="jah32370-tbl-0004" ref-type="table-wrap">4</xref>), associations were generally attenuated and became nonsignificant for non&#x02010;HDL&#x02010;c and apoB. Tertile analysis demonstrated a graded increase in risk with increasing levels of these markers but not LDL&#x02010;c (Table&#x000a0;<xref rid="jah32370-tbl-0005" ref-type="table-wrap">5</xref>).</p><fig fig-type="Figure" xml:lang="en" id="jah32370-fig-0003" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Adjusted* <styled-content style="fixed-case">HR</styled-content> and 95%<styled-content style="fixed-case">CI</styled-content> for the primary incident <styled-content style="fixed-case">CVD</styled-content> end point in the <styled-content style="fixed-case">JUPITER</styled-content> placebo group associated with baseline marker levels. ApoB indicates apolipoprotein B; <styled-content style="fixed-case">CM</styled-content>, chylomicrons; <styled-content style="fixed-case">HR</styled-content>, hazard ratio; <styled-content style="fixed-case">IDL</styled-content>&#x02010;p, intermediate density lipoprotein particle concentration; <styled-content style="fixed-case">JUPITER</styled-content>, Justification for the Use of Statins in Prevention: an Intervention Trial; <styled-content style="fixed-case">LDL</styled-content>&#x02010;c, low&#x02010;density lipoprotein cholesterol; <styled-content style="fixed-case">LDL</styled-content>&#x02010;p, low&#x02010;density lipoprotein particle concentration; non&#x02010;<styled-content style="fixed-case">HDL</styled-content>&#x02010;c, non&#x02010;high&#x02010;density lipoprotein cholesterol concentration; <styled-content style="fixed-case">RC</styled-content>, calculated remnant cholesterol; <styled-content style="fixed-case">TG</styled-content>, triglycerides; <styled-content style="fixed-case">VLDL</styled-content>&#x02010;c, very low&#x02010;density lipoprotein cholesterol; <styled-content style="fixed-case">VLDL</styled-content>&#x02010;p, very low&#x02010;density lipoprotein particle concentration. *Adjusted for age, sex, race, smoking status, family history of premature coronary disease, body&#x02010;mass index, systolic blood pressure, fasting glucose, and hs<styled-content style="fixed-case">CRP</styled-content>. <sup>&#x02020;</sup>
<styled-content style="fixed-case">LDL</styled-content> size was no longer associated with either end point after adjusting for <styled-content style="fixed-case">LDL</styled-content>&#x02010;p and <styled-content style="fixed-case">HDL</styled-content>&#x02010;c. The following biomarkers were natural&#x02010;log&#x02010;transformed: triglyceride, <styled-content style="fixed-case">RC</styled-content>, small <styled-content style="fixed-case">LDL</styled-content>&#x02010;p, <styled-content style="fixed-case">IDL</styled-content>&#x02010;p, all <styled-content style="fixed-case">VLDL</styled-content>&#x02010;p subclasses, <styled-content style="fixed-case">VLDL</styled-content>/<styled-content style="fixed-case">CM</styled-content> triglycerides, and <styled-content style="fixed-case">VLDL</styled-content>&#x02010;c.</p></caption><graphic id="nlm-graphic-5" xlink:href="JAH3-6-e005549-g003"/></fig><table-wrap id="jah32370-tbl-0004" xml:lang="en" orientation="portrait" position="float"><label>Table 4</label><caption><p>Adjusted HR and 95%CI for the Expanded End Point (Incident CVD and All&#x02010;Cause Mortality) in the Placebo Group at Baseline and the Rosuvastatin Group On&#x02010;Treatment</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="3" valign="top" colspan="1"/><th align="left" colspan="2" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Baseline Risk (Placebo; N=6050)</th><th align="left" colspan="2" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Residual Risk (Rosuvatatin; N=4386)</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" colspan="2" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">CVD and All&#x02010;Cause Death</th><th align="left" colspan="2" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">CVD and All&#x02010;Cause Death</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">HR per 1 SD Higher<xref ref-type="fn" rid="jah32370-note-0008">a</xref> (95%CI)</th><th align="left" valign="top" rowspan="1" colspan="1">
<italic>P</italic> Value</th><th align="left" valign="top" rowspan="1" colspan="1">HR per 1 SD Higher<xref ref-type="fn" rid="jah32370-note-0008">a</xref>, <xref ref-type="fn" rid="jah32370-note-0009">b</xref> (95%CI)</th><th align="left" valign="top" rowspan="1" colspan="1">
<italic>P</italic> Value</th></tr></thead><tbody><tr><td align="left" colspan="5" rowspan="1">Lipids and apolipoproteins (SD), mg/dL</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">LDL&#x02010;c</td><td align="left" rowspan="1" colspan="1">0.90 (0.80, 1.00)</td><td align="left" rowspan="1" colspan="1">0.061</td><td align="left" rowspan="1" colspan="1">1.14 (1.02, 1.28)</td><td align="left" rowspan="1" colspan="1">0.024</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Non&#x02010;HDL&#x02010;c</td><td align="left" rowspan="1" colspan="1">1.00 (0.88, 1.12)</td><td align="left" rowspan="1" colspan="1">0.979</td><td align="left" rowspan="1" colspan="1">1.16 (1.02, 1.32)</td><td align="left" rowspan="1" colspan="1">0.023</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Apolipoprotein B</td><td align="left" rowspan="1" colspan="1">1.06 (0.94, 1.19)</td><td align="left" rowspan="1" colspan="1">0.352</td><td align="left" rowspan="1" colspan="1">1.19 (1.01, 1.40)</td><td align="left" rowspan="1" colspan="1">0.033</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Triglycerides<xref ref-type="fn" rid="jah32370-note-0010">c</xref>
</td><td align="left" rowspan="1" colspan="1">1.18 (1.05, 1.33)</td><td align="left" rowspan="1" colspan="1">0.005</td><td align="left" rowspan="1" colspan="1">1.10 (0.89, 1.36)</td><td align="left" rowspan="1" colspan="1">0.391</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">RC<xref ref-type="fn" rid="jah32370-note-0010">c</xref>
</td><td align="left" rowspan="1" colspan="1">1.19 (1.05, 1.33)</td><td align="left" rowspan="1" colspan="1">0.005</td><td align="left" rowspan="1" colspan="1">1.10 (0.89, 1.37)</td><td align="left" rowspan="1" colspan="1">0.390</td></tr><tr><td align="left" colspan="5" rowspan="1">NMR lipoproteins (SD)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">LDL size</td><td align="left" rowspan="1" colspan="1">0.85 (0.75, 0.95)</td><td align="left" rowspan="1" colspan="1">0.006</td><td align="left" rowspan="1" colspan="1">1.21 (0.98, 1.50)</td><td align="left" rowspan="1" colspan="1">0.081</td></tr><tr><td align="left" style="padding-left:10%" colspan="5" rowspan="1">LDL&#x02010;p</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Total</td><td align="left" rowspan="1" colspan="1">1.01 (0.89, 1.14)</td><td align="left" rowspan="1" colspan="1">0.923</td><td align="left" rowspan="1" colspan="1">1.07 (0.88, 1.31)</td><td align="left" rowspan="1" colspan="1">0.504</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Large</td><td align="left" rowspan="1" colspan="1">0.93 (0.82, 1.05)</td><td align="left" rowspan="1" colspan="1">0.218</td><td align="left" rowspan="1" colspan="1">1.18 (0.95, 1.47)</td><td align="left" rowspan="1" colspan="1">0.144</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Small<xref ref-type="fn" rid="jah32370-note-0010">c</xref>
</td><td align="left" rowspan="1" colspan="1">0.97 (0.86, 1.08)</td><td align="left" rowspan="1" colspan="1">0.518</td><td align="left" rowspan="1" colspan="1">0.87 (0.72, 1.05)</td><td align="left" rowspan="1" colspan="1">0.153</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">IDL&#x02010;p<xref ref-type="fn" rid="jah32370-note-0010">c</xref>
</td><td align="left" rowspan="1" colspan="1">0.98 (0.87, 1.10)</td><td align="left" rowspan="1" colspan="1">0.746</td><td align="left" rowspan="1" colspan="1">0.98 (0.83, 1.15)</td><td align="left" rowspan="1" colspan="1">0.760</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">VLDL size</td><td align="left" rowspan="1" colspan="1">1.08 (0.96, 1.21)</td><td align="left" rowspan="1" colspan="1">0.206</td><td align="left" rowspan="1" colspan="1">0.72 (0.57, 0.91)</td><td align="left" rowspan="1" colspan="1">0.005</td></tr><tr><td align="left" style="padding-left:10%" colspan="5" rowspan="1">VLDL&#x02010;p</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Total<xref ref-type="fn" rid="jah32370-note-0010">c</xref>
</td><td align="left" rowspan="1" colspan="1">1.25 (1.11, 1.41)</td><td align="left" rowspan="1" colspan="1">0.0003</td><td align="left" rowspan="1" colspan="1">1.32 (1.08, 1.61)</td><td align="left" rowspan="1" colspan="1">0.006</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Large<xref ref-type="fn" rid="jah32370-note-0010">c</xref>
</td><td align="left" rowspan="1" colspan="1">1.19 (1.05, 1.35)</td><td align="left" rowspan="1" colspan="1">0.001</td><td align="left" rowspan="1" colspan="1">1.03 (0.85, 1.26)</td><td align="left" rowspan="1" colspan="1">0.762</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Medium<xref ref-type="fn" rid="jah32370-note-0010">c</xref>
</td><td align="left" rowspan="1" colspan="1">1.22 (1.08, 1.39)</td><td align="left" rowspan="1" colspan="1">0.002</td><td align="left" rowspan="1" colspan="1">1.04 (0.84, 1.27)</td><td align="left" rowspan="1" colspan="1">0.741</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Small<xref ref-type="fn" rid="jah32370-note-0010">c</xref>
</td><td align="left" rowspan="1" colspan="1">1.16 (1.04, 1.29)</td><td align="left" rowspan="1" colspan="1">0.007</td><td align="left" rowspan="1" colspan="1">1.56 (1.25, 1.95)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">VLDL/chylomicron triglycerides <xref ref-type="fn" rid="jah32370-note-0010">c</xref>
</td><td align="left" rowspan="1" colspan="1">1.27 (1.13, 1.42)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="left" rowspan="1" colspan="1">1.10 (0.91, 1.34)</td><td align="left" rowspan="1" colspan="1">0.325</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">VLDL&#x02010;c<xref ref-type="fn" rid="jah32370-note-0010">c</xref>
</td><td align="left" rowspan="1" colspan="1">1.10 (0.95, 1.27)</td><td align="left" rowspan="1" colspan="1">0.211</td><td align="left" rowspan="1" colspan="1">1.27 (1.05, 1.54)</td><td align="left" rowspan="1" colspan="1">0.014</td></tr></tbody></table><table-wrap-foot><fn id="jah32370-note-0007"><p>CHD indicates coronary heart disease; CVD, cardiovascular disease; HDL, high&#x02010;density lipoprotein; hsCRP, high&#x02010;sensitivity C&#x02010;reactive protein; IDL, intermediate&#x02010;density lipoprotein; LDL&#x02010;c, low&#x02010;density lipoprotein cholesterol; LDL&#x02010;p, low density lipoprotein particle concentration; NMR, nuclear magnetic resonance; non&#x02010;HDL&#x02010;c, non&#x02010;high density lipoprotein cholesterol concentration; RC, remnant cholesterol; VLDL&#x02010;c, very low density lipoprotein cholesterol; VLDL&#x02010;p, very low density lipoprotein particle concentration.</p></fn><fn id="jah32370-note-0008"><label>a</label><p>Adjusted for age, race, sex, race, family history of CHD, smoking, systolic blood pressure, fasting glucose, body mass index, and the natural logarithm of hsCRP.</p></fn><fn id="jah32370-note-0009"><label>b</label><p>Baseline SDs used to allow for comparison.</p></fn><fn id="jah32370-note-0010"><label>c</label><p>Variable was log&#x02010;transformed (ln), and risk is per change in SD of the natural log of the variable.</p></fn></table-wrap-foot></table-wrap><table-wrap id="jah32370-tbl-0005" xml:lang="en" orientation="portrait" position="float"><label>Table 5</label><caption><p>Baseline Lipid and Lipoproteins by Tertile in Relation to End Points in the Placebo Arm</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" valign="top" colspan="1"/><th align="left" colspan="4" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Adjusted HR (95%CI)<xref ref-type="fn" rid="jah32370-note-0012">a</xref>
</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">Lowest Tertile</th><th align="left" valign="top" rowspan="1" colspan="1">Middle Tertile</th><th align="left" valign="top" rowspan="1" colspan="1">Highest Tertile</th><th align="left" valign="top" rowspan="1" colspan="1">
<italic>P</italic>
<sub>trend</sub>
<xref ref-type="fn" rid="jah32370-note-0013">b</xref>
</th></tr></thead><tbody><tr><td align="left" colspan="5" rowspan="1">Lipids and apolipoproteins</td></tr><tr><td align="left" style="padding-left:10%" colspan="5" rowspan="1">LDL&#x02010;c</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Range, mg/dL</td><td align="left" rowspan="1" colspan="1">&#x02264;100</td><td align="left" rowspan="1" colspan="1">100 to 116</td><td align="left" rowspan="1" colspan="1">&#x0003e;116</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Primary end point</td><td align="left" rowspan="1" colspan="1">Ref</td><td align="left" rowspan="1" colspan="1">0.99 (0.71, 1.14)</td><td align="left" rowspan="1" colspan="1">1.08 (0.76, 1.55)</td><td align="left" rowspan="1" colspan="1">0.66</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Secondary end point</td><td align="left" rowspan="1" colspan="1">Ref</td><td align="left" rowspan="1" colspan="1">0.77 (0.59, 1.00)</td><td align="left" rowspan="1" colspan="1">0.85 (0.64, 1.12)</td><td align="left" rowspan="1" colspan="1">0.22</td></tr><tr><td align="left" style="padding-left:10%" colspan="5" rowspan="1">Non&#x02010;HDL&#x02010;c</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Range, mg/dL</td><td align="left" rowspan="1" colspan="1">&#x02264;125</td><td align="left" rowspan="1" colspan="1">125 to 143</td><td align="left" rowspan="1" colspan="1">&#x0003e;143</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Primary end point</td><td align="left" rowspan="1" colspan="1">Ref</td><td align="left" rowspan="1" colspan="1">1.18 (0.82, 1.69)</td><td align="left" rowspan="1" colspan="1">1.33 (0.93, 1.92)</td><td align="left" rowspan="1" colspan="1">0.122</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Secondary end point</td><td align="left" rowspan="1" colspan="1">Ref</td><td align="left" rowspan="1" colspan="1">0.99 (0.75, 1.31)</td><td align="left" rowspan="1" colspan="1">1.06 (0.80, 1.41)</td><td align="left" rowspan="1" colspan="1">0.700</td></tr><tr><td align="left" style="padding-left:10%" colspan="5" rowspan="1">Apolipoprotein B</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Range, mg/dL</td><td align="left" rowspan="1" colspan="1">&#x02264;101</td><td align="left" rowspan="1" colspan="1">101 to 117</td><td align="left" rowspan="1" colspan="1">&#x0003e;117</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Primary end point</td><td align="left" rowspan="1" colspan="1">Ref</td><td align="left" rowspan="1" colspan="1">1.42 (1.00, 2.05)</td><td align="left" rowspan="1" colspan="1">1.54 (1.06, 2.22)</td><td align="left" rowspan="1" colspan="1">0.024</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Secondary end point</td><td align="left" rowspan="1" colspan="1">Ref</td><td align="left" rowspan="1" colspan="1">1.09 (0.83, 1.44)</td><td align="left" rowspan="1" colspan="1">1.06 (0.79, 1.41)</td><td align="left" rowspan="1" colspan="1">0.701</td></tr><tr><td align="left" style="padding-left:10%" colspan="5" rowspan="1">Triglycerides</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Range, mg/dL</td><td align="left" rowspan="1" colspan="1">&#x02264;96</td><td align="left" rowspan="1" colspan="1">96 to 147</td><td align="left" rowspan="1" colspan="1">&#x0003e;147</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Primary end point</td><td align="left" rowspan="1" colspan="1">Ref</td><td align="left" rowspan="1" colspan="1">1.59 (1.08, 2.33)</td><td align="left" rowspan="1" colspan="1">1.84 (1.26, 2.69)</td><td align="left" rowspan="1" colspan="1">0.002</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Secondary end point</td><td align="left" rowspan="1" colspan="1">Ref</td><td align="left" rowspan="1" colspan="1">1.40 (1.03, 1.88)</td><td align="left" rowspan="1" colspan="1">1.57 (1.16, 2.11)</td><td align="left" rowspan="1" colspan="1">0.003</td></tr><tr><td align="left" colspan="5" rowspan="1">NMR lipoproteins</td></tr><tr><td align="left" style="padding-left:10%" colspan="5" rowspan="1">LDL size</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Range, nm</td><td align="left" rowspan="1" colspan="1">&#x02264;20.7</td><td align="left" rowspan="1" colspan="1">20.7 to 21.2</td><td align="left" rowspan="1" colspan="1">&#x0003e;21.2</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Primary end point</td><td align="left" rowspan="1" colspan="1">Ref</td><td align="left" rowspan="1" colspan="1">0.67 (0.47, 0.97)</td><td align="left" rowspan="1" colspan="1">0.77 (0.54, 1.09)</td><td align="left" rowspan="1" colspan="1">0.131</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Secondary end point</td><td align="left" rowspan="1" colspan="1">Ref</td><td align="left" rowspan="1" colspan="1">0.67 (0.50, 0.89)</td><td align="left" rowspan="1" colspan="1">0.72 (0.54, 0.95)</td><td align="left" rowspan="1" colspan="1">0.019</td></tr><tr><td align="left" style="padding-left:10%" colspan="5" rowspan="1">LDL&#x02010;p</td></tr><tr><td align="left" style="padding-left:15%" colspan="5" rowspan="1">Total</td></tr><tr><td align="left" style="padding-left:20%" rowspan="1" colspan="1">Range, nmol/L</td><td align="left" rowspan="1" colspan="1">&#x02264;1147</td><td align="left" rowspan="1" colspan="1">1147 to 1390</td><td align="left" rowspan="1" colspan="1">&#x0003e;1390</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:20%" rowspan="1" colspan="1">Primary end point</td><td align="left" rowspan="1" colspan="1">Ref</td><td align="left" rowspan="1" colspan="1">1.38 (0.95, 2.00)</td><td align="left" rowspan="1" colspan="1">1.57 (1.09, 2.28)</td><td align="left" rowspan="1" colspan="1">0.017</td></tr><tr><td align="left" style="padding-left:20%" rowspan="1" colspan="1">Secondary end point</td><td align="left" rowspan="1" colspan="1">Ref</td><td align="left" rowspan="1" colspan="1">1.12 (0.85, 1.48)</td><td align="left" rowspan="1" colspan="1">1.03 (0.77, 1.38)</td><td align="left" rowspan="1" colspan="1">0.828</td></tr><tr><td align="left" style="padding-left:15%" colspan="5" rowspan="1">Large</td></tr><tr><td align="left" style="padding-left:20%" rowspan="1" colspan="1">Range</td><td align="left" rowspan="1" colspan="1">&#x02264;364</td><td align="left" rowspan="1" colspan="1">364 to 557</td><td align="left" rowspan="1" colspan="1">&#x0003e;557</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:20%" rowspan="1" colspan="1">Primary end point</td><td align="left" rowspan="1" colspan="1">Ref</td><td align="left" rowspan="1" colspan="1">0.75 (0.52, 1.09)</td><td align="left" rowspan="1" colspan="1">1.03 (0.73, 1.45)</td><td align="left" rowspan="1" colspan="1">0.849</td></tr><tr><td align="left" style="padding-left:20%" rowspan="1" colspan="1">Secondary end point</td><td align="left" rowspan="1" colspan="1">Ref</td><td align="left" rowspan="1" colspan="1">0.76 (0.57, 1.01)</td><td align="left" rowspan="1" colspan="1">0.90 (0.68, 1.19)</td><td align="left" rowspan="1" colspan="1">0.466</td></tr><tr><td align="left" style="padding-left:15%" colspan="5" rowspan="1">Small</td></tr><tr><td align="left" style="padding-left:20%" rowspan="1" colspan="1">Range, nmol/L</td><td align="left" rowspan="1" colspan="1">&#x02264;485</td><td align="left" rowspan="1" colspan="1">485 to 728</td><td align="left" rowspan="1" colspan="1">&#x0003e;728</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:20%" rowspan="1" colspan="1">Primary end point</td><td align="left" rowspan="1" colspan="1">Ref</td><td align="left" rowspan="1" colspan="1">1.29 (0.89, 1.88)</td><td align="left" rowspan="1" colspan="1">1.44 (0.99, 2.10)</td><td align="left" rowspan="1" colspan="1">0.059</td></tr><tr><td align="left" style="padding-left:20%" rowspan="1" colspan="1">secondary end point</td><td align="left" rowspan="1" colspan="1">Ref</td><td align="left" rowspan="1" colspan="1">1.13 (0.85, 1.51)</td><td align="left" rowspan="1" colspan="1">1.14 (0.84, 1.53)</td><td align="left" rowspan="1" colspan="1">0.402</td></tr><tr><td align="left" style="padding-left:15%" colspan="5" rowspan="1">IDL&#x02010;p</td></tr><tr><td align="left" style="padding-left:20%" rowspan="1" colspan="1">Range</td><td align="left" rowspan="1" colspan="1">&#x02264;115</td><td align="left" rowspan="1" colspan="1">115 to 193</td><td align="left" rowspan="1" colspan="1">&#x0003e;193</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:20%" rowspan="1" colspan="1">Primary end point</td><td align="left" rowspan="1" colspan="1">Ref</td><td align="left" rowspan="1" colspan="1">1.15 (0.82, 1.63)</td><td align="left" rowspan="1" colspan="1">0.99 (0.69, 1.42)</td><td align="left" rowspan="1" colspan="1">0.967</td></tr><tr><td align="left" style="padding-left:20%" rowspan="1" colspan="1">Secondary end point</td><td align="left" rowspan="1" colspan="1">Ref</td><td align="left" rowspan="1" colspan="1">1.08 (0.82, 1.42)</td><td align="left" rowspan="1" colspan="1">1.02 (0.76, 1.36)</td><td align="left" rowspan="1" colspan="1">0.893</td></tr><tr><td align="left" style="padding-left:10%" colspan="5" rowspan="1">VLDL size</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Range, nm</td><td align="left" rowspan="1" colspan="1">&#x02264;45.6</td><td align="left" rowspan="1" colspan="1">45.6 to 51.7</td><td align="left" rowspan="1" colspan="1">&#x0003e;51.7</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Primary end point</td><td align="left" rowspan="1" colspan="1">Ref</td><td align="left" rowspan="1" colspan="1">1.23 (0.86, 1.77)</td><td align="left" rowspan="1" colspan="1">1.30 (0.90, 1.88)</td><td align="left" rowspan="1" colspan="1">0.164</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Secondary end point</td><td align="left" rowspan="1" colspan="1">Ref</td><td align="left" rowspan="1" colspan="1">1.31 (0.99, 1.75)</td><td align="left" rowspan="1" colspan="1">1.26 (0.93, 1.69)</td><td align="left" rowspan="1" colspan="1">0.128</td></tr><tr><td align="left" style="padding-left:10%" colspan="5" rowspan="1">VLDL&#x02010;p</td></tr><tr><td align="left" style="padding-left:15%" colspan="5" rowspan="1">Total</td></tr><tr><td align="left" style="padding-left:20%" rowspan="1" colspan="1">Range, nmol/L</td><td align="left" rowspan="1" colspan="1">&#x02264;34.6</td><td align="left" rowspan="1" colspan="1">34.6 to 53.2</td><td align="left" rowspan="1" colspan="1">&#x0003e;53.2</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:20%" rowspan="1" colspan="1">Primary end point</td><td align="left" rowspan="1" colspan="1">Ref</td><td align="left" rowspan="1" colspan="1">1.14 (0.77, 1.66)</td><td align="left" rowspan="1" colspan="1">1.55 (1.08, 2.21)</td><td align="left" rowspan="1" colspan="1">0.014</td></tr><tr><td align="left" style="padding-left:20%" rowspan="1" colspan="1">Secondary end point</td><td align="left" rowspan="1" colspan="1">Ref</td><td align="left" rowspan="1" colspan="1">1.21 (0.90, 1.64)</td><td align="left" rowspan="1" colspan="1">1.54 (1.15, 2.05)</td><td align="left" rowspan="1" colspan="1">0.003</td></tr><tr><td align="left" style="padding-left:15%" colspan="5" rowspan="1">Large</td></tr><tr><td align="left" style="padding-left:20%" rowspan="1" colspan="1">Range, nmol/L</td><td align="left" rowspan="1" colspan="1">&#x02264;1.7</td><td align="left" rowspan="1" colspan="1">1.7 to 4.0</td><td align="left" rowspan="1" colspan="1">&#x0003e;4.0</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:20%" rowspan="1" colspan="1">Primary end point</td><td align="left" rowspan="1" colspan="1">Ref</td><td align="left" rowspan="1" colspan="1">1.45 (1.01, 2.07)</td><td align="left" rowspan="1" colspan="1">1.26 (0.86, 1.84)</td><td align="left" rowspan="1" colspan="1">0.246</td></tr><tr><td align="left" style="padding-left:20%" rowspan="1" colspan="1">Secondary end point</td><td align="left" rowspan="1" colspan="1">Ref</td><td align="left" rowspan="1" colspan="1">1.44 (1.08, 1.93)</td><td align="left" rowspan="1" colspan="1">1.41 (1.04, 1.90)</td><td align="left" rowspan="1" colspan="1">0.028</td></tr><tr><td align="left" style="padding-left:15%" colspan="5" rowspan="1">Medium</td></tr><tr><td align="left" style="padding-left:20%" rowspan="1" colspan="1">Range, nmol/L</td><td align="left" rowspan="1" colspan="1">&#x02264;8.1</td><td align="left" rowspan="1" colspan="1">8.1 to 15.7</td><td align="left" rowspan="1" colspan="1">&#x0003e;15.7</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:20%" rowspan="1" colspan="1">Primary end point</td><td align="left" rowspan="1" colspan="1">Ref</td><td align="left" rowspan="1" colspan="1">1.36 (0.92, 2.00)</td><td align="left" rowspan="1" colspan="1">1.79 (1.24, 2.60)</td><td align="left" rowspan="1" colspan="1">0.002</td></tr><tr><td align="left" style="padding-left:20%" rowspan="1" colspan="1">Secondary end point</td><td align="left" rowspan="1" colspan="1">Ref</td><td align="left" rowspan="1" colspan="1">1.18 (0.87, 1.60)</td><td align="left" rowspan="1" colspan="1">1.72 (1.28, 2.29)</td><td align="left" rowspan="1" colspan="1">0.0002</td></tr><tr><td align="left" style="padding-left:15%" colspan="5" rowspan="1">Small</td></tr><tr><td align="left" style="padding-left:20%" rowspan="1" colspan="1">Range, nmol/L</td><td align="left" rowspan="1" colspan="1">&#x02264;20.9</td><td align="left" rowspan="1" colspan="1">20.9 to 34.3</td><td align="left" rowspan="1" colspan="1">&#x0003e;34.3</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:20%" rowspan="1" colspan="1">Primary end point</td><td align="left" rowspan="1" colspan="1">Ref</td><td align="left" rowspan="1" colspan="1">1.12 (0.77, 1.62)</td><td align="left" rowspan="1" colspan="1">1.31 (0.91, 1.86)</td><td align="left" rowspan="1" colspan="1">0.139</td></tr><tr><td align="left" style="padding-left:20%" rowspan="1" colspan="1">Secondary end point</td><td align="left" rowspan="1" colspan="1">Ref</td><td align="left" rowspan="1" colspan="1">1.31 (0.97, 1.78)</td><td align="left" rowspan="1" colspan="1">1.45 (1.08, 1.95)</td><td align="left" rowspan="1" colspan="1">0.014</td></tr><tr><td align="left" style="padding-left:10%" colspan="5" rowspan="1">VLDL triglycerides</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Range, mg/dL</td><td align="left" rowspan="1" colspan="1">&#x02264;49.1</td><td align="left" rowspan="1" colspan="1">49.1 to 77.5</td><td align="left" rowspan="1" colspan="1">&#x0003e;77.5</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Primary end point</td><td align="left" rowspan="1" colspan="1">Ref</td><td align="left" rowspan="1" colspan="1">1.30 (0.89, 1.89)</td><td align="left" rowspan="1" colspan="1">1.49 (1.03, 2.16)</td><td align="left" rowspan="1" colspan="1">0.035</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Secondary end point</td><td align="left" rowspan="1" colspan="1">Ref</td><td align="left" rowspan="1" colspan="1">1.29 (0.96, 1.75)</td><td align="left" rowspan="1" colspan="1">1.59 (1.18, 2.13)</td><td align="left" rowspan="1" colspan="1">0.002</td></tr></tbody></table><table-wrap-foot><fn id="jah32370-note-0011"><p>Tertiles derived from the baseline population. HR indicates hazard ratio; hsCRP, high&#x02010;sensitivity C&#x02010;reactive protein; IDL&#x02010;p, intermediate&#x02010;density particle concentration; LDL&#x02010;c, low&#x02010;density lipoprotein cholesterol; LDL&#x02010;p, low&#x02010;density lipoprotein particle concentration; non&#x02010;HDL&#x02010;c, non&#x02010;high&#x02010;density lipoprotein cholesterol concentration; RC, remnant cholesterol; Ref, reference value; VLDL&#x02010;c, very low&#x02010;density lipoprotein cholesterol; VLDL&#x02010;p, very low&#x02010;density lipoprotein particle concentration.</p></fn><fn id="jah32370-note-0012"><label>a</label><p>Adjusted for adjusted for age, sex, race, smoking status, family history of premature coronary disease, body&#x02010;mass index, systolic blood pressure, fasting glucose, and hsCRP.</p></fn><fn id="jah32370-note-0013"><label>b</label><p>
<italic>P</italic> for nonlinear trend.</p></fn></table-wrap-foot></table-wrap><p>For NMR&#x02010;measured lipoproteins, a significant association was noted for LDL&#x02010;p and the primary end point (1.19 [1.02, 1.38]) but not for the individual LDL subclasses. Smaller LDL size was a marker of increased risk, but this was no longer significant after additionally adjusting for LDL&#x02010;p&#x02014;as previously suggested<xref rid="jah32370-bib-0016" ref-type="ref">16</xref>&#x02014;and HDL&#x02010;c.</p><p>Conversely, most VLDL&#x02010;p subfractions, as well as total VLDL&#x02010;p and NMR&#x02010;determined VLDL/CM triglycerides, were associated with increased risk of the primary (Figure&#x000a0;<xref rid="jah32370-fig-0003" ref-type="fig">3</xref>) or expanded (Table&#x000a0;<xref rid="jah32370-tbl-0004" ref-type="table-wrap">4</xref>) end point. The magnitude of this risk was similar to that of chemically measured triglycerides. Because VLDL&#x02010;p subfractions were comparably associated with increased risk, there was no independent association for average VLDL particle size. Total NMR&#x02010;measured VLDL&#x02010;c was not significantly associated with the primary or expanded end points at baseline. Overall, when the baseline analysis was performed in the entire cohort adjusting for known randomized statin allocation as a covariable, the results were similar.</p></sec><sec id="jah32370-sec-0019"><title>Lipoprotein Subclass Response to Statin Therapy</title><p>Rosuvastatin therapy produced large median (25th, 75th percentile) percentage reductions in LDL&#x02010;c (&#x02212;49.0 [&#x02212;58.2, &#x02212;32.8]%), apoB (&#x02212;39.4 [&#x02212;47.6, &#x02212;26.7]%), and non&#x02010;HDL&#x02010;c (&#x02212;42.7 [&#x02212;51.1, &#x02212;27.7]%; Figure&#x000a0;<xref rid="jah32370-fig-0004" ref-type="fig">4</xref>; Table&#x000a0;<xref rid="jah32370-tbl-0003" ref-type="table-wrap">3</xref>) and resulted in greater reductions in large (&#x02212;57.5 [&#x02212;77.0, &#x02212;24.4]%) versus small (&#x02212;22.1 [&#x02212;42.8, 4.5]%) LDL&#x02010;p. Triglycerides and VLDL&#x02010;p subfractions showed smaller, more variable responses to statin therapy, and many participants had no reduction after a year of statin therapy.</p><fig fig-type="Figure" xml:lang="en" id="jah32370-fig-0004" orientation="portrait" position="float"><label>Figure 4</label><caption><p>Median percentage change in lipids, apoB, and <styled-content style="fixed-case">NMR</styled-content>&#x02010;measured lipoprotein subclasses in the placebo and statin&#x02010;treated arms in <styled-content style="fixed-case">JUPITER</styled-content>. Error bars represent 25th and 75th percentiles. <styled-content style="fixed-case">CM</styled-content> indicates chylomicrons; <styled-content style="fixed-case">IDL</styled-content>&#x02010;p, intermediate&#x02010;density lipoprotein particle concentration; <styled-content style="fixed-case">JUPITER</styled-content>, Justification for the Use of Statins in Prevention: an Intervention Trial; <styled-content style="fixed-case">LDL</styled-content>&#x02010;c, low&#x02010;density lipoprotein cholesterol; <styled-content style="fixed-case">LDL</styled-content>&#x02010;p, low&#x02010;density lipoprotein particle concentration; NMR, nuclear magnetic resonance; non&#x02010;<styled-content style="fixed-case">HDL</styled-content>&#x02010;c, non&#x02010;high&#x02010;density lipoprotein cholesterol concentration; <styled-content style="fixed-case">RC</styled-content>, calculated remnant cholesterol; <styled-content style="fixed-case">TG</styled-content>, triglycerides; <styled-content style="fixed-case">VLDL</styled-content>&#x02010;c, very low&#x02010;density lipoprotein cholesterol; <styled-content style="fixed-case">VLDL</styled-content>&#x02010;p, very low density lipoprotein particle concentration.</p></caption><graphic id="nlm-graphic-7" xlink:href="JAH3-6-e005549-g004"/></fig></sec><sec id="jah32370-sec-0020"><title>Residual Risk of CVD</title><p>Among participants in the statin&#x02010;allocated arm with on&#x02010;statin measures (N=4386), median LDL&#x02010;c was 55&#x000a0;mg/dL, and triglyceride was 102&#x000a0;mg/dL. In this population, standard lipid and apolipoprotein measures were marginally associated with risk (73 primary end&#x02010;point events and 108 expanded end&#x02010;point events; Figure&#x000a0;<xref rid="jah32370-fig-0005" ref-type="fig">5</xref>; Tables&#x000a0;<xref rid="jah32370-tbl-0004" ref-type="table-wrap">4</xref> and <xref rid="jah32370-tbl-0006" ref-type="table-wrap">6</xref>), including apoB, non&#x02010;HDL&#x02010;c, and LDL&#x02010;c.</p><fig fig-type="Figure" xml:lang="en" id="jah32370-fig-0005" orientation="portrait" position="float"><label>Figure 5</label><caption><p>On&#x02010;statin adjusted* <styled-content style="fixed-case">HR</styled-content> and 95%<styled-content style="fixed-case">CI</styled-content> for the primary incident <styled-content style="fixed-case">CVD</styled-content> end point in the <styled-content style="fixed-case">JUPITER</styled-content> rosuvastatin 20&#x02010;mg group. <styled-content style="fixed-case">CM</styled-content> indicates chylomicrons; <styled-content style="fixed-case">HR</styled-content>, hazard ratio; <styled-content style="fixed-case">IDL</styled-content>&#x02010;p, intermediate&#x02010;density lipoprotein particle concentration; <styled-content style="fixed-case">JUPITER</styled-content>, Justification for the Use of Statins in Prevention: an Intervention Trial; <styled-content style="fixed-case">LDL</styled-content>&#x02010;c, low&#x02010;density lipoprotein cholesterol; <styled-content style="fixed-case">LDL</styled-content>&#x02010;p, low&#x02010;density lipoprotein particle concentration; non&#x02010;<styled-content style="fixed-case">HDL</styled-content>&#x02010;c, non&#x02010;high&#x02010;density lipoprotein cholesterol concentration; <styled-content style="fixed-case">RC</styled-content>, calculated remnant cholesterol; <styled-content style="fixed-case">SD</styled-content>, standard deviation; <styled-content style="fixed-case">TG</styled-content>, triglycerides; <styled-content style="fixed-case">VLDL</styled-content>&#x02010;c, very low&#x02010;density lipoprotein cholesterol; <styled-content style="fixed-case">VLDL</styled-content>&#x02010;p, very low&#x02010;density lipoprotein particle concentration. *Adjusted for age, sex, race, smoking status, family history of premature coronary disease, body&#x02010;mass index, systolic blood pressure, fasting glucose, and hs<styled-content style="fixed-case">CRP</styled-content>. The following biomarkers were natural&#x02010;log&#x02010;transformed: triglyceride, <styled-content style="fixed-case">RC</styled-content>, small <styled-content style="fixed-case">LDL</styled-content>&#x02010;p, <styled-content style="fixed-case">IDL</styled-content>&#x02010;p, all <styled-content style="fixed-case">VLDL</styled-content>&#x02010;p subclasses, <styled-content style="fixed-case">VLDL</styled-content>/<styled-content style="fixed-case">CM</styled-content> triglycerides, and <styled-content style="fixed-case">VLDL</styled-content>&#x02010;c.</p></caption><graphic id="nlm-graphic-9" xlink:href="JAH3-6-e005549-g005"/></fig><table-wrap id="jah32370-tbl-0006" xml:lang="en" orientation="portrait" position="float"><label>Table 6</label><caption><p>On&#x02010;Treatment Lipid and Lipoproteins by Tertile in Relation to End Points in the Rosuvastatin Arm</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" valign="top" colspan="1"/><th align="left" colspan="4" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Adjusted HR (95%CI)<xref ref-type="fn" rid="jah32370-note-0015">a</xref>
</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">Lowest Tertile</th><th align="left" valign="top" rowspan="1" colspan="1">Middle Tertile</th><th align="left" valign="top" rowspan="1" colspan="1">Highest Tertile</th><th align="left" valign="top" rowspan="1" colspan="1">
<italic>P</italic>
<sub>trend</sub>
<xref ref-type="fn" rid="jah32370-note-0016">b</xref>
</th></tr></thead><tbody><tr><td align="left" colspan="5" rowspan="1">Lipids and apolipoproteins</td></tr><tr><td align="left" style="padding-left:10%" colspan="5" rowspan="1">LDL&#x02010;c</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Range, mg/dL</td><td align="left" rowspan="1" colspan="1">&#x02264;47</td><td align="left" rowspan="1" colspan="1">47 to 63</td><td align="left" rowspan="1" colspan="1">&#x0003e;63</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Primary end point</td><td align="left" rowspan="1" colspan="1">Ref</td><td align="left" rowspan="1" colspan="1">0.74 (0.39, 1.42)</td><td align="left" rowspan="1" colspan="1">1.73 (1.00, 2.98)</td><td align="left" rowspan="1" colspan="1">0.034</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Secondary end point</td><td align="left" rowspan="1" colspan="1">Ref</td><td align="left" rowspan="1" colspan="1">0.69 (0.41, 1.17)</td><td align="left" rowspan="1" colspan="1">1.41 (0.91, 2.21)</td><td align="left" rowspan="1" colspan="1">0.099</td></tr><tr><td align="left" style="padding-left:10%" colspan="5" rowspan="1">Non&#x02010;HDL&#x02010;c</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Range, mg/dL</td><td align="left" rowspan="1" colspan="1">&#x02264;68</td><td align="left" rowspan="1" colspan="1">68 to 87</td><td align="left" rowspan="1" colspan="1">&#x0003e;87</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Primary end point</td><td align="left" rowspan="1" colspan="1">Ref</td><td align="left" rowspan="1" colspan="1">0.80 (0.43, 1.49)</td><td align="left" rowspan="1" colspan="1">1.53 (0.89, 2.63)</td><td align="left" rowspan="1" colspan="1">0.111</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Secondary end point</td><td align="left" rowspan="1" colspan="1">Ref</td><td align="left" rowspan="1" colspan="1">0.81 (0.48, 1.34)</td><td align="left" rowspan="1" colspan="1">1.60 (1.02, 2.50)</td><td align="left" rowspan="1" colspan="1">0.030</td></tr><tr><td align="left" style="padding-left:10%" colspan="5" rowspan="1">Apolipoprotein B</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Range, mg/dL</td><td align="left" rowspan="1" colspan="1">&#x02264;60</td><td align="left" rowspan="1" colspan="1">60 to 75</td><td align="left" rowspan="1" colspan="1">&#x0003e;75</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Primary end point</td><td align="left" rowspan="1" colspan="1">Ref</td><td align="left" rowspan="1" colspan="1">0.99 (0.54, 1.80)</td><td align="left" rowspan="1" colspan="1">1.47 (0.83, 2.58)</td><td align="left" rowspan="1" colspan="1">0.169</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Secondary end point</td><td align="left" rowspan="1" colspan="1">Ref</td><td align="left" rowspan="1" colspan="1">0.95 (0.57, 1.58)</td><td align="left" rowspan="1" colspan="1">1.55 (0.98, 2.47)</td><td align="left" rowspan="1" colspan="1">0.049</td></tr><tr><td align="left" style="padding-left:10%" colspan="5" rowspan="1">Triglycerides</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Range, mg/dL</td><td align="left" rowspan="1" colspan="1">&#x02264;85</td><td align="left" rowspan="1" colspan="1">85 to 122</td><td align="left" rowspan="1" colspan="1">&#x0003e;122</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Primary end point</td><td align="left" rowspan="1" colspan="1">Ref</td><td align="left" rowspan="1" colspan="1">0.98 (0.55, 1.74)</td><td align="left" rowspan="1" colspan="1">1.04 (0.59, 1.85)</td><td align="left" rowspan="1" colspan="1">0.883</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Secondary end point</td><td align="left" rowspan="1" colspan="1">Ref</td><td align="left" rowspan="1" colspan="1">1.05 (0.65, 1.68)</td><td align="left" rowspan="1" colspan="1">1.17 (0.73, 1.88)</td><td align="left" rowspan="1" colspan="1">0.506</td></tr><tr><td align="left" colspan="5" rowspan="1">NMR lipoproteins</td></tr><tr><td align="left" style="padding-left:10%" colspan="5" rowspan="1">LDL size</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Range, nm</td><td align="left" rowspan="1" colspan="1">&#x02264;20.3</td><td align="left" rowspan="1" colspan="1">20.3 to 20.8</td><td align="left" rowspan="1" colspan="1">&#x0003e;20.8</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Primary end point</td><td align="left" rowspan="1" colspan="1">Ref</td><td align="left" rowspan="1" colspan="1">0.75 (0.40, 1.40)</td><td align="left" rowspan="1" colspan="1">1.58 (0.91, 2.72)</td><td align="left" rowspan="1" colspan="1">0.100</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Secondary end point</td><td align="left" rowspan="1" colspan="1">Ref</td><td align="left" rowspan="1" colspan="1">0.74 (0.44, 1.25)</td><td align="left" rowspan="1" colspan="1">1.48 (0.94, 2.32)</td><td align="left" rowspan="1" colspan="1">0.078</td></tr><tr><td align="left" style="padding-left:10%" colspan="5" rowspan="1">LDL&#x02010;p</td></tr><tr><td align="left" style="padding-left:15%" colspan="5" rowspan="1">Total</td></tr><tr><td align="left" style="padding-left:20%" rowspan="1" colspan="1">Range, nmol/L</td><td align="left" rowspan="1" colspan="1">&#x02264;678</td><td align="left" rowspan="1" colspan="1">678 to 879</td><td align="left" rowspan="1" colspan="1">&#x0003e;879</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:20%" rowspan="1" colspan="1">Primary end point</td><td align="left" rowspan="1" colspan="1">Ref</td><td align="left" rowspan="1" colspan="1">0.96 (0.54, 1.71)</td><td align="left" rowspan="1" colspan="1">1.09 (0.61, 1.92)</td><td align="left" rowspan="1" colspan="1">0.772</td></tr><tr><td align="left" style="padding-left:20%" rowspan="1" colspan="1">Secondary end point</td><td align="left" rowspan="1" colspan="1">Ref</td><td align="left" rowspan="1" colspan="1">0.74 (0.45, 1.22)</td><td align="left" rowspan="1" colspan="1">1.14 (0.73, 1.79)</td><td align="left" rowspan="1" colspan="1">0.528</td></tr><tr><td align="left" style="padding-left:15%" colspan="5" rowspan="1">Large</td></tr><tr><td align="left" style="padding-left:20%" rowspan="1" colspan="1">Range</td><td align="left" rowspan="1" colspan="1">&#x02264;117</td><td align="left" rowspan="1" colspan="1">117 to 246</td><td align="left" rowspan="1" colspan="1">&#x0003e;246</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:20%" rowspan="1" colspan="1">Primary end point</td><td align="left" rowspan="1" colspan="1">Ref</td><td align="left" rowspan="1" colspan="1">1.34 (0.75, 2.39)</td><td align="left" rowspan="1" colspan="1">1.38 (0.76, 2.50)</td><td align="left" rowspan="1" colspan="1">0.296</td></tr><tr><td align="left" style="padding-left:20%" rowspan="1" colspan="1">Secondary end point</td><td align="left" rowspan="1" colspan="1">Ref</td><td align="left" rowspan="1" colspan="1">1.03 (0.64, 1.68)</td><td align="left" rowspan="1" colspan="1">1.28 (0.80, 2.06)</td><td align="left" rowspan="1" colspan="1">0.291</td></tr><tr><td align="left" style="padding-left:15%" colspan="5" rowspan="1">Small</td></tr><tr><td align="left" style="padding-left:20%" rowspan="1" colspan="1">Range, nmol/L</td><td align="left" rowspan="1" colspan="1">&#x02264;415</td><td align="left" rowspan="1" colspan="1">415 to 572</td><td align="left" rowspan="1" colspan="1">&#x0003e;572</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:20%" rowspan="1" colspan="1">Primary end point</td><td align="left" rowspan="1" colspan="1">Ref</td><td align="left" rowspan="1" colspan="1">0.69 (0.40, 1.22)</td><td align="left" rowspan="1" colspan="1">0.63 (0.36, 1.13)</td><td align="left" rowspan="1" colspan="1">0.117</td></tr><tr><td align="left" style="padding-left:20%" rowspan="1" colspan="1">Secondary end point</td><td align="left" rowspan="1" colspan="1">Ref</td><td align="left" rowspan="1" colspan="1">0.69 (0.43, 1.11)</td><td align="left" rowspan="1" colspan="1">0.81 (0.51, 1.28)</td><td align="left" rowspan="1" colspan="1">0.361</td></tr><tr><td align="left" style="padding-left:15%" colspan="5" rowspan="1">IDL&#x02010;p</td></tr><tr><td align="left" style="padding-left:20%" rowspan="1" colspan="1">Range</td><td align="left" rowspan="1" colspan="1">&#x02264;62</td><td align="left" rowspan="1" colspan="1">62 to 106</td><td align="left" rowspan="1" colspan="1">&#x0003e;106</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:20%" rowspan="1" colspan="1">Primary end point</td><td align="left" rowspan="1" colspan="1">Ref</td><td align="left" rowspan="1" colspan="1">0.80 (0.48, 1.36)</td><td align="left" rowspan="1" colspan="1">0.49 (0.27, 0.91)</td><td align="left" rowspan="1" colspan="1">0.024</td></tr><tr><td align="left" style="padding-left:20%" rowspan="1" colspan="1">Secondary end point</td><td align="left" rowspan="1" colspan="1">Ref</td><td align="left" rowspan="1" colspan="1">0.79 (0.50, 1.23)</td><td align="left" rowspan="1" colspan="1">0.67 (0.42, 1.07)</td><td align="left" rowspan="1" colspan="1">0.090</td></tr><tr><td align="left" style="padding-left:10%" colspan="5" rowspan="1">VLDL size</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Range, nm</td><td align="left" rowspan="1" colspan="1">&#x02264;47.4</td><td align="left" rowspan="1" colspan="1">47.4 to 53.1</td><td align="left" rowspan="1" colspan="1">&#x0003e;53.1</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Primary end point</td><td align="left" rowspan="1" colspan="1">Ref</td><td align="left" rowspan="1" colspan="1">0.83 (0.50, 1.38)</td><td align="left" rowspan="1" colspan="1">0.31 (0.15, 0.63)</td><td align="left" rowspan="1" colspan="1">0.002</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Secondary end point</td><td align="left" rowspan="1" colspan="1">Ref</td><td align="left" rowspan="1" colspan="1">0.81 (0.53, 1.23)</td><td align="left" rowspan="1" colspan="1">0.40 (0.23, 0.70)</td><td align="left" rowspan="1" colspan="1">0.001</td></tr><tr><td align="left" style="padding-left:10%" colspan="5" rowspan="1">VLDL&#x02010;p</td></tr><tr><td align="left" style="padding-left:15%" colspan="5" rowspan="1">Total</td></tr><tr><td align="left" style="padding-left:20%" rowspan="1" colspan="1">Range, nmol/L</td><td align="left" rowspan="1" colspan="1">&#x02264;27.0</td><td align="left" rowspan="1" colspan="1">27.0 to 41.3</td><td align="left" rowspan="1" colspan="1">&#x0003e;41.3</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:20%" rowspan="1" colspan="1">Primary end point</td><td align="left" rowspan="1" colspan="1">Ref</td><td align="left" rowspan="1" colspan="1">1.40 (0.75, 2.61)</td><td align="left" rowspan="1" colspan="1">1.67 (0.92, 3.04)</td><td align="left" rowspan="1" colspan="1">0.095</td></tr><tr><td align="left" style="padding-left:20%" rowspan="1" colspan="1">Secondary end point</td><td align="left" rowspan="1" colspan="1">Ref</td><td align="left" rowspan="1" colspan="1">1.29 (0.78, 2.14)</td><td align="left" rowspan="1" colspan="1">1.59 (0.98, 2.58)</td><td align="left" rowspan="1" colspan="1">0.059</td></tr><tr><td align="left" style="padding-left:15%" colspan="5" rowspan="1">Large</td></tr><tr><td align="left" style="padding-left:20%" rowspan="1" colspan="1">Range, nmol/L</td><td align="left" rowspan="1" colspan="1">&#x02264;1.4</td><td align="left" rowspan="1" colspan="1">1.4 to 3.3</td><td align="left" rowspan="1" colspan="1">&#x0003e;3.3</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:20%" rowspan="1" colspan="1">Primary end point</td><td align="left" rowspan="1" colspan="1">Ref</td><td align="left" rowspan="1" colspan="1">1.94 (1.11, 3.38)</td><td align="left" rowspan="1" colspan="1">1.01 (0.53, 1.91)</td><td align="left" rowspan="1" colspan="1">0.929</td></tr><tr><td align="left" style="padding-left:20%" rowspan="1" colspan="1">Secondary end point</td><td align="left" rowspan="1" colspan="1">Ref</td><td align="left" rowspan="1" colspan="1">1.63 (1.04, 2.56)</td><td align="left" rowspan="1" colspan="1">0.94 (0.56, 1.56)</td><td align="left" rowspan="1" colspan="1">0.898</td></tr><tr><td align="left" style="padding-left:15%" colspan="5" rowspan="1">Medium</td></tr><tr><td align="left" style="padding-left:20%" rowspan="1" colspan="1">Range, nmol/L</td><td align="left" rowspan="1" colspan="1">&#x02264;7.9</td><td align="left" rowspan="1" colspan="1">7.9 to 14.4</td><td align="left" rowspan="1" colspan="1">&#x0003e;14.4</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:20%" rowspan="1" colspan="1">Primary end point</td><td align="left" rowspan="1" colspan="1">Ref</td><td align="left" rowspan="1" colspan="1">0.84 (0.48, 1.49)</td><td align="left" rowspan="1" colspan="1">0.85 (0.49, 1.50)</td><td align="left" rowspan="1" colspan="1">0.582</td></tr><tr><td align="left" style="padding-left:20%" rowspan="1" colspan="1">Secondary end point</td><td align="left" rowspan="1" colspan="1">Ref</td><td align="left" rowspan="1" colspan="1">0.97 (0.61, 1.55)</td><td align="left" rowspan="1" colspan="1">0.96 (0.60, 1.54)</td><td align="left" rowspan="1" colspan="1">0.865</td></tr><tr><td align="left" style="padding-left:15%" colspan="5" rowspan="1">Small</td></tr><tr><td align="left" style="padding-left:20%" rowspan="1" colspan="1">Range, nmol/L</td><td align="left" rowspan="1" colspan="1">&#x02264;14.5</td><td align="left" rowspan="1" colspan="1">14.5 to 24.3</td><td align="left" rowspan="1" colspan="1">&#x0003e;24.3</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:20%" rowspan="1" colspan="1">Primary end point</td><td align="left" rowspan="1" colspan="1">Ref</td><td align="left" rowspan="1" colspan="1">2.29 (1.09, 4.82)</td><td align="left" rowspan="1" colspan="1">3.73 (1.86, 7.49)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" style="padding-left:20%" rowspan="1" colspan="1">Secondary end point</td><td align="left" rowspan="1" colspan="1">Ref</td><td align="left" rowspan="1" colspan="1">1.97 (1.13, 3.43)</td><td align="left" rowspan="1" colspan="1">2.56 (1.51, 4.34)</td><td align="left" rowspan="1" colspan="1">0.0005</td></tr><tr><td align="left" style="padding-left:10%" colspan="5" rowspan="1">VLDL triglycerides</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Range, mg/dL</td><td align="left" rowspan="1" colspan="1">&#x02264;41.1</td><td align="left" rowspan="1" colspan="1">41.1 to 64.4</td><td align="left" rowspan="1" colspan="1">&#x0003e;64.4</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">primary end point</td><td align="left" rowspan="1" colspan="1">Ref</td><td align="left" rowspan="1" colspan="1">1.32 (0.74, 2.35)</td><td align="left" rowspan="1" colspan="1">1.17 (0.64, 2.12)</td><td align="left" rowspan="1" colspan="1">0.629</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Secondary end point</td><td align="left" rowspan="1" colspan="1">Ref</td><td align="left" rowspan="1" colspan="1">1.16 (0.72, 1.87)</td><td align="left" rowspan="1" colspan="1">1.24 (0.77, 2.01)</td><td align="left" rowspan="1" colspan="1">0.375</td></tr></tbody></table><table-wrap-foot><fn id="jah32370-note-0014"><p>Tertiles derived from on&#x02010;treatment (rosuvastatin) group at 12&#x000a0;months. HR indicates hazard ratio; hsCRP, high&#x02010;sensitivity C&#x02010;reactive protein; IDL&#x02010;p, intermediate&#x02010;density particle concentration; LDL&#x02010;c, low&#x02010;density lipoprotein cholesterol; LDL&#x02010;p, low&#x02010;density lipoprotein particle concentration; non&#x02010;HDL&#x02010;c, non&#x02010;high&#x02010;density lipoprotein cholesterol concentration; RC, remnant cholesterol; Ref, reference value; VLDL&#x02010;c, very low density lipoprotein cholesterol; VLDL&#x02010;p, very low density lipoprotein particle concentration.</p></fn><fn id="jah32370-note-0015"><label>a</label><p>Adjusted for adjusted for age, sex, race, smoking status, family history of premature coronary disease, body&#x02010;mass index, systolic blood pressure, fasting glucose, and hsCRP.</p></fn><fn id="jah32370-note-0016"><label>b</label><p>
<italic>P</italic> for nonlinear trend.</p></fn></table-wrap-foot></table-wrap><p>On statin therapy, each SD increment in total VLDL&#x02010;p, driven by the smallest VLDL&#x02010;p subclass, was associated with residual risk (Figure&#x000a0;<xref rid="jah32370-fig-0005" ref-type="fig">5</xref>). Adjusted hazard ratios (95%CIs) per increasing tertile of on&#x02010;treatment small VLDL&#x02010;p were 1.00 (Ref.), 2.29 (1.09, 4.82), and 3.73 (1.86, 7.49), <italic>P</italic> for trend &#x0003c;0.0001 (Table&#x000a0;<xref rid="jah32370-tbl-0006" ref-type="table-wrap">6</xref>). For each SD greater average VLDL size, reflecting a shift away from small VLDL&#x02010;p, there was a 40% relative risk reduction. In sensitivity analyses these associations remained significant after adjustment for other NMR lipoproteins (1.83 [1.35, 2.50]) and incrementally for HDL&#x02010;c (1.77 [1.29, 2.43]) or HDL&#x02010;p (1.78 [1.31, 2.43]). On&#x02010;treatment NMR&#x02010;measured VLDL&#x02010;c was associated with both the primary and expanded end points. This risk was driven by the cholesterol contained in the small VLDL subclass (primary end point 1.74 [1.32, 2.30]; expanded end point 1.59 [1.27, 1.98]). In contrast, no associations were found for on&#x02010;treatment triglycerides, NMR&#x02010;measured VLDL/CM triglycerides, formulaic remnant cholesterol, or large and medium VLDL&#x02010;p subfractions.</p></sec><sec id="jah32370-sec-0021"><title>Secondary Cohort Examination</title><p>Participants in CATHGEN with LDL&#x02010;c &#x0003c;130&#x000a0;mg/dL and triglycerides &#x0003c;500&#x000a0;mg/dL were demographically similar to JUPITER participants in age (mean [SD] 60.7&#x000b1;11.7&#x000a0;years), sex (62.3% male), and racial (74.2% white) distribution as well as based on body&#x02010;mass index (30.1&#x000b1;7.4&#x000a0;kg/m<sup>2</sup>) and systolic blood pressure (144&#x000b1;25&#x000a0;mm&#x000a0;Hg). Among these 2149 individuals, 154 events occurred over median (maximum) 5.0 (13.3) years of follow&#x02010;up. Total VLDL&#x02010;p was significantly associated with risk of myocardial infarction, driven by the small VLDL lipoprotein subclass (Table&#x000a0;<xref rid="jah32370-tbl-0007" ref-type="table-wrap">7</xref>). As with larger VLDL&#x02010;p subclasses, VLDL/CM triglyceride concentration was not significantly associated with risk. Although restriction to those confirmed as having a prescribed statin reduced sample size to only 833 individuals, the pattern of the associations was unchanged, but the confidence intervals in this much smaller subgroup were wider and no longer significant. When no LDL&#x02010;c or statin&#x02010;based selection criteria were applied, risk of myocardial infarction among all comers with NMR measurements in the cohort was not significantly associated with VLDL&#x02010;p levels. Similarly, the magnitude of risk associated with LDL&#x02010;p became larger as the cohort was progressively more selected based on LDL&#x02010;c &#x0003c;130&#x000a0;mg/dL and statin prescription status.</p><table-wrap id="jah32370-tbl-0007" xml:lang="en" orientation="portrait" position="float"><label>Table 7</label><caption><p>Adjusted HR (95%CI) for Myocardial Infarction Among Participants in the CATHGEN Registry (Replication Cohort), Among All Comers, Those With LDL&#x02010;c &#x0003c;130&#x000a0;mg/dL and Triglyceride &#x0003c;500&#x000a0;mg/dL, as Well as Those With Confirmed Statin Prescription at Time of NMR Measurement</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" valign="top" colspan="1"/><th align="left" colspan="3" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">CATHGEN Registry: Adjusted HR<xref ref-type="fn" rid="jah32370-note-0018">a</xref> (95%CI) of Myocardial Infarction Per&#x02010;1 SD Incremental Increase in Lipoprotein</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" style="border-bottom:solid 1px #000000" valign="top" rowspan="1" colspan="1">All Participants (n=4721; 346 Cases)</th><th align="left" style="border-bottom:solid 1px #000000" valign="top" rowspan="1" colspan="1">LDL&#x02010;c &#x0003c;130&#x000a0;mg/dL TG &#x0003c;500&#x000a0;mg/dL (n=2149; 154 Events)</th><th align="left" style="border-bottom:solid 1px #000000" valign="top" rowspan="1" colspan="1">Statin Prescription (n=833; 59 Events)</th></tr></thead><tbody><tr><td align="left" colspan="4" rowspan="1">LDL&#x02010;p</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Total</td><td align="left" rowspan="1" colspan="1">1.17 (1.05, 1.31)</td><td align="left" rowspan="1" colspan="1">1.28 (1.07, 1.52)</td><td align="left" rowspan="1" colspan="1">1.61 (1.20, 2.14)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Large</td><td align="left" rowspan="1" colspan="1">1.02 (0.91, 1.14)</td><td align="left" rowspan="1" colspan="1">0.92 (0.79, 1.08)</td><td align="left" rowspan="1" colspan="1">1.33 (0.99, 1.80)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Small<xref ref-type="fn" rid="jah32370-note-0019">b</xref>
</td><td align="left" rowspan="1" colspan="1">1.12 (0.99, 1.26)</td><td align="left" rowspan="1" colspan="1">1.21 (0.99, 1.49)</td><td align="left" rowspan="1" colspan="1">1.54 (1.04, 2.29)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">IDL&#x02010;p<xref ref-type="fn" rid="jah32370-note-0019">b</xref>
</td><td align="left" rowspan="1" colspan="1">0.97 (0.87, 1.07)</td><td align="left" rowspan="1" colspan="1">0.95 (0.81, 1.12)</td><td align="left" rowspan="1" colspan="1">0.93 (0.71, 1.21)</td></tr><tr><td align="left" colspan="4" rowspan="1">VLDL&#x02010;p</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Total<xref ref-type="fn" rid="jah32370-note-0019">b</xref>
</td><td align="left" rowspan="1" colspan="1">1.11 (0.98, 1.26)</td><td align="left" rowspan="1" colspan="1">1.23 (1.01, 1.51)</td><td align="left" rowspan="1" colspan="1">1.19 (0.86, 1.63)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Large<xref ref-type="fn" rid="jah32370-note-0019">b</xref>
</td><td align="left" rowspan="1" colspan="1">0.96 (0.86, 1.07)</td><td align="left" rowspan="1" colspan="1">1.01 (0.86, 1.19)</td><td align="left" rowspan="1" colspan="1">1.04 (0.80, 1.36)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Medium<xref ref-type="fn" rid="jah32370-note-0019">b</xref>
</td><td align="left" rowspan="1" colspan="1">1.01 (0.90, 1.13)</td><td align="left" rowspan="1" colspan="1">1.03 (0.87, 1.22)</td><td align="left" rowspan="1" colspan="1">1.11 (0.83, 1.48)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Small<xref ref-type="fn" rid="jah32370-note-0019">b</xref>
</td><td align="left" rowspan="1" colspan="1">1.10 (0.97, 1.24)</td><td align="left" rowspan="1" colspan="1">1.27 (1.02, 1.57)</td><td align="left" rowspan="1" colspan="1">1.35 (0.96, 1.90)</td></tr><tr><td align="left" rowspan="1" colspan="1">TG (VLDL/CM)<xref ref-type="fn" rid="jah32370-note-0019">b</xref>
</td><td align="left" rowspan="1" colspan="1">1.06 (0.94, 1.18)</td><td align="left" rowspan="1" colspan="1">1.12 (0.94, 1.32)</td><td align="left" rowspan="1" colspan="1">1.10 (0.83, 1.46)</td></tr></tbody></table><table-wrap-foot><fn id="jah32370-note-0017"><p>CHD indicates coronary heart disease; CM, chylomicrons; IDL&#x02010;p, intermediate&#x02010;density lipoprotein particle concentration; LDL&#x02010;p, low&#x02010;density lipoprotein particle concentration; RC, remnant cholesterol; TG, triglycerides; VLDL&#x02010;p, very low&#x02010;density lipoprotein particle concentration.</p></fn><fn id="jah32370-note-0018"><label>a</label><p>Adjusted for age, race, sex, family history of CHD, smoking, systolic blood pressure, fasting glucose, and body mass index.</p></fn><fn id="jah32370-note-0019"><label>b</label><p>Variable was log&#x02010;transformed (ln), and risk is per change in SD of the natural log of the variable.</p></fn></table-wrap-foot></table-wrap></sec><sec id="jah32370-sec-0022"><title>Prediction Model Performance</title><p>In JUPITER the C&#x02010;statistic (a measure of model discrimination) for the baseline CVD risk model (built with 12 clinical and standard lipid measure variables; 12 degrees of freedom) for the placebo group was not significantly changed (<italic>P</italic>=0.50) with the addition of all NMR lipoprotein measures (24 variables): 0.664 (95%CI=0.618, 0.710) to 0.668 (0.623, 0.714). A baseline parsimonious model (which statistically selected among the 24 candidate variables those that most significantly contributed to CVD prediction) identified age, sex, smoking, family history, and medium VLDL&#x02010;p as top predictor variables. Conversely for residual risk models, discrimination was significantly improved by a model that included all of the NMR variables (24 degrees of freedom) compared to a model with only clinical and standard lipid variables (12 degrees of freedom): C=0.780 (0.718, 0.842) versus 0.712 (0.636, 0.788); <italic>P</italic>=0.0001. The parsimonious model for residual risk selected age, sex, smoking, hsCRP, VLDL&#x02010;c, small LDL&#x02010;p, and VLDL size as top predictors.</p></sec></sec><sec id="jah32370-sec-0023"><title>Discussion</title><p>This study was designed to identify circulating lipoproteins measured by <sup>1</sup>H NMR associated with CVD risk among individuals with naturally or pharmacologically low (&#x0003c;130&#x000a0;mg/dL) LDL&#x02010;c. We observed that, among such individuals, risk was associated with lipoprotein particle concentration, including LDL and VLDL subfractions. Intriguingly, among individuals on statin therapy (median LDL&#x02010;c 55&#x000a0;mg/dL), the lipoprotein subclass small VLDL&#x02010;p (and its associated cholesterol) conferred an &#x02248;70% per&#x02010;SD increase in residual risk, corresponding to a 3.7&#x02010;fold increase in risk among those in the highest tertile. These observations were extended using a distinct, diverse cohort referred for cardiac catheterization (CATHGEN); as refinement of the population based on LDL&#x02010;c &#x0003c;130&#x000a0;mg/dL or statin prescription was undertaken, the magnitude of risk related to lipoprotein subclasses appeared amplified (including small VLDL&#x02010;p). Exploratory analyses suggested that on&#x02010;statin residual risk prediction could be significantly improved beyond known clinical and standard lipid risk factors with the inclusion of NMR&#x02010;based VLDL measurements. Overall, our results suggest a potential role for VLDL lipoproteins in the development of CVD events, particularly among individuals with lower LDL&#x02010;c&#x02014;a rapidly growing population in clinical practice<xref rid="jah32370-bib-0001" ref-type="ref">1</xref>, <xref rid="jah32370-bib-0002" ref-type="ref">2</xref> in whom event rates nonetheless remain unacceptably high.<xref rid="jah32370-bib-0003" ref-type="ref">3</xref>, <xref rid="jah32370-bib-0017" ref-type="ref">17</xref>
</p><p>We observed that baseline apoB and LDL&#x02010;p were associated with risk of incident CVD. Although both measures were highly correlated (<italic>r</italic>=0.79), the magnitude of risk associated with&#x000a0;apoB was somewhat greater than that for LDL&#x02010;p, consistent with findings from the Women's Health Study.<xref rid="jah32370-bib-0014" ref-type="ref">14</xref> In addition to LDL, apoB is also present on VLDL and lipoprotein(a), the latter of which also carried increased risk in JUPITER.<xref rid="jah32370-bib-0018" ref-type="ref">18</xref>
</p><p>Triglycerides and VLDL/CM measures were associated with risk in the JUPITER placebo group, whereas the small VLDL&#x02010;p subclass (but not triglycerides) was strongly associated with risk in the statin group. VLDL (also referred to as triglyceride&#x02010;rich lipoproteins) are believed to confer atherogenic risk related to their cholesterol content (ie, remnant cholesterol),<xref rid="jah32370-bib-0019" ref-type="ref">19</xref> which can be deposited directly into the arterial wall without modification.<xref rid="jah32370-bib-0020" ref-type="ref">20</xref> Why the magnitude of risk related to VLDL&#x02010;p appeared to differ based on statin allocation is unclear and deserves further investigation. It is possible that statin&#x02010;related suppression of inflammation could modify the relationship between VLDL and atherosclerosis.<xref rid="jah32370-bib-0019" ref-type="ref">19</xref>
</p><p>Our study is novel in its consideration of NMR&#x02010;based atherogenic lipoprotein measures among dedicated populations of individuals with low (&#x0003c;130&#x000a0;mg/dL) LDL&#x02010;c, an increasingly prevalent population in the era of LDL&#x02010;c reduction. Our findings support and extend previous observations from other cohorts, wherein lipoprotein particle concentration measured by apoB and NMR (LDL&#x02010;p) was associated with CVD events among statin&#x02010;treated secondary prevention individuals.<xref rid="jah32370-bib-0021" ref-type="ref">21</xref> Additionally, no other study has assessed the significance of on&#x02010;statin levels of NMR&#x02010;measured VLDL lipoproteins in relation to residual CVD risk. Our results help frame those of previous studies, wherein on&#x02010;statin triglyceride levels have been inconsistently associated with residual risk,<xref rid="jah32370-bib-0022" ref-type="ref">22</xref> suggesting the need for more detailed VLDL phenotyping. Our results also support and extend recent efforts to more comprehensively profile statin effects on the spectrum of the lipid and lipoprotein milieu.<xref rid="jah32370-bib-0023" ref-type="ref">23</xref>
</p><p>The risk estimates observed with NMR are largely in agreement with those recently obtained in the same cohort using electrospray ion mobility,<xref rid="jah32370-bib-0024" ref-type="ref">24</xref> except that stronger association was noted for NMR&#x02010;measured small VLDL&#x02010;p with residual risk. In JUPITER, measurements of small VLDL by NMR and ion mobility were only modestly correlated (Spearman <italic>r</italic>=0.22). In other cohorts, NMR and ion mobility have also demonstrated differential resolution of the proatherogenic effects of VLDL.<xref rid="jah32370-bib-0025" ref-type="ref">25</xref> The basis for such differences may be due to methodological differences, with NMR providing better measurement of lipid&#x02010;rich lipoprotein particles such as VLDL, while ion mobility may better capture protein&#x02010;rich particles.</p><p>Our study has several potential limitations. First, the follow&#x02010;up duration in JUPITER was relatively short for a primary prevention study (due to early termination of the trial for benefit by the Data Safety and Monitoring Board). Nonetheless, event rates were sufficiently high to detect a number of expected and novel associations, and the longer follow&#x02010;up in CATHGEN (median [maximum] 5.0 [13.3] years) suggested longitudinal extrapolation of these results. Second, all JUPITER study participants had elevated hsCRP. Systemic inflammation has been shown to affect the composition of the lipoprotein milieu, including VLDL.<xref rid="jah32370-bib-0026" ref-type="ref">26</xref> At a minimum, it has been estimated that more than 1 in 50 adult Americans would meet the JUPITER inclusion criteria.<xref rid="jah32370-bib-0027" ref-type="ref">27</xref> Furthermore, hsCRP was not part of the selection criteria in CATHGEN, suggesting that these findings may be more broadly generalizable. Finally, multiple comparisons were performed, increasing the chance of a type I error. However, examination of an independent cohort supported the key associations observed, and the findings are supported by prior biologic and epidemiological studies. Nonetheless, given the multiplicity of hypotheses tested, these results should be viewed as hypothesis&#x02010;generating and require further validation in additional cohorts.</p></sec><sec id="jah32370-sec-0024"><title>Conclusions</title><p>In conclusion, among individuals with low (&#x0003c;130&#x000a0;mg/dL) LDL&#x02010;c, risk remains associated with lipoprotein particle concentration, including VLDL lipoproteins. We observed on&#x02010;statin risk strongly associated with small VLDL&#x02010;p&#x02014;risk that appears to be triglyceride&#x02010;independent and instead related to the cholesterol carried by these small VLDL particles. Overall, these hypothesis&#x02010;generating findings draw attention to the potential importance of VLDL lipoproteins, in particular small remnant particles, which are associated with risk but are currently not the target of prediction or therapeutic intervention. Additional studies are needed to validate these findings and assess the potential causal role of these lipoproteins as determinants of CVD risk.</p></sec><sec id="jah32370-sec-0025"><title>Sources of Funding</title><p>Lawler received support from NIH T32 (HL007575), NIH Loan Repayment Program, and Brigham and Women's Hospital, and currently receives support from the Peter Munk Cardiac Centre, University Health Network, the University of Toronto, and the Heart and Stroke/Richard Lewar Center for Excellence in Cardiovascular Research. Akinkoulie receives support from NIH T32 (HL007575). The research for this article was supported by the National Heart, Lung, and Blood Institute of the NIH under Award Numbers R01HL117861 and R01HL117861&#x02010;S1 and &#x02010;S2 to Mora, and by the Molino Family Trust. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. The funding agency had no role in the design and execution of the current study. The JUPITER trial (NCT00239681) was funded by AstraZeneca, who had no role in the design and execution of this study. LipoScience (now LabCorp) performed the NMR lipoprotein analysis for this study at no additional cost.</p></sec><sec id="jah32370-sec-0026"><title>Disclosures</title><p>Mora received research grant support from Atherotech Diagnostics for research outside the current work and served as a consultant to Amgen, Lilly, Pfizer, Cerenis Therapeutics, and Quest Diagnostics. Glynn received research grant support from AstraZeneca. Ridker received research grant support from AstraZeneca, Kowa, Novartis, Amgen, Pfizer, and NHLBI and is listed as a coinventor on patents held by the Brigham and Women's Hospital related to the use of inflammatory biomarkers in CVD (licensed to AstraZeneca and Siemens). All other authors report no disclosures. Shah, Craig, and Kraus received research funding from LipoScience (now LabCorp) during this funding period. Chu is currently an employee at Merck but was not during the conduct of this study.</p></sec></body><back><ref-list content-type="cited-references" id="jah32370-bibl-0001"><title>References</title><ref id="jah32370-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="jah32370-cit-0001">
<string-name>
<surname>Rosinger</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Carroll</surname>
<given-names>MD</given-names>
</string-name>, <string-name>
<surname>Lacher</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Ogden</surname>
<given-names>C</given-names>
</string-name>. <article-title>Trends in total cholesterol, triglycerides, and low&#x02010;density lipoprotein in US adults, 1999&#x02013;2014</article-title>. <source>JAMA Cardiol</source>. <year>2017</year>;<volume>2</volume>:<fpage>339</fpage>&#x02013;<lpage>341</lpage>.<pub-id pub-id-type="pmid">27902824</pub-id></mixed-citation></ref><ref id="jah32370-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="jah32370-cit-0002">
<string-name>
<surname>Kuklina</surname>
<given-names>EV</given-names>
</string-name>, <string-name>
<surname>Yoon</surname>
<given-names>PW</given-names>
</string-name>, <string-name>
<surname>Keenan</surname>
<given-names>NL</given-names>
</string-name>. <article-title>Trends in high levels of low&#x02010;density lipoprotein cholesterol in the United States, 1999&#x02013;2006</article-title>. <source>JAMA</source>. <year>2009</year>;<volume>302</volume>:<fpage>2104</fpage>&#x02013;<lpage>2110</lpage>.<pub-id pub-id-type="pmid">19920234</pub-id></mixed-citation></ref><ref id="jah32370-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="jah32370-cit-0003">
<string-name>
<surname>Baigent</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Keech</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Kearney</surname>
<given-names>PM</given-names>
</string-name>, <string-name>
<surname>Blackwell</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Buck</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Pollicino</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Kirby</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Sourjina</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Peto</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Collins</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Simes</surname>
<given-names>R</given-names>
</string-name>; <collab collab-type="authors">Cholesterol Treatment Trialists' Collaborators</collab>
. <article-title>Efficacy and safety of cholesterol&#x02010;lowering treatment: prospective meta&#x02010;analysis of data from 90,056 participants in 14 randomised trials of statins</article-title>. <source>Lancet</source>. <year>2005</year>;<volume>366</volume>:<fpage>1267</fpage>&#x02013;<lpage>1278</lpage>.<pub-id pub-id-type="pmid">16214597</pub-id></mixed-citation></ref><ref id="jah32370-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="jah32370-cit-0004">
<string-name>
<surname>van Lammeren</surname>
<given-names>GW</given-names>
</string-name>, <string-name>
<surname>den Ruijter</surname>
<given-names>HM</given-names>
</string-name>, <string-name>
<surname>Vrijenhoek</surname>
<given-names>JE</given-names>
</string-name>, <string-name>
<surname>van der Laan</surname>
<given-names>SW</given-names>
</string-name>, <string-name>
<surname>Velema</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>de Vries</surname>
<given-names>JP</given-names>
</string-name>, <string-name>
<surname>de Kleijn</surname>
<given-names>DP</given-names>
</string-name>, <string-name>
<surname>Vink</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>de Borst</surname>
<given-names>GJ</given-names>
</string-name>, <string-name>
<surname>Moll</surname>
<given-names>FL</given-names>
</string-name>, <string-name>
<surname>Bots</surname>
<given-names>ML</given-names>
</string-name>, <string-name>
<surname>Pasterkamp</surname>
<given-names>G</given-names>
</string-name>. <article-title>Time&#x02010;dependent changes in atherosclerotic plaque composition in patients undergoing carotid surgery</article-title>. <source>Circulation</source>. <year>2014</year>;<volume>129</volume>:<fpage>2269</fpage>&#x02013;<lpage>2276</lpage>.<pub-id pub-id-type="pmid">24637558</pub-id></mixed-citation></ref><ref id="jah32370-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="jah32370-cit-0005">
<string-name>
<surname>Libby</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Pasterkamp</surname>
<given-names>G</given-names>
</string-name>. <article-title>Requiem for the &#x02018;vulnerable plaque&#x02019;</article-title>. <source>Eur Heart J</source>. <year>2015</year>;<volume>36</volume>:<fpage>2984</fpage>&#x02013;<lpage>2987</lpage>.<pub-id pub-id-type="pmid">26206212</pub-id></mixed-citation></ref><ref id="jah32370-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="jah32370-cit-0006">
<string-name>
<surname>Sniderman</surname>
<given-names>AD</given-names>
</string-name>, <string-name>
<surname>Williams</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Contois</surname>
<given-names>JH</given-names>
</string-name>, <string-name>
<surname>Monroe</surname>
<given-names>HM</given-names>
</string-name>, <string-name>
<surname>McQueen</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>de Graaf</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Furberg</surname>
<given-names>CD</given-names>
</string-name>. <article-title>A meta&#x02010;analysis of low&#x02010;density lipoprotein cholesterol, non&#x02010;high&#x02010;density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk</article-title>. <source>Circ Cardiovasc Qual Outcomes</source>. <year>2011</year>;<volume>4</volume>:<fpage>337</fpage>&#x02013;<lpage>345</lpage>.<pub-id pub-id-type="pmid">21487090</pub-id></mixed-citation></ref><ref id="jah32370-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="jah32370-cit-0007">
<string-name>
<surname>Boekholdt</surname>
<given-names>SM</given-names>
</string-name>, <string-name>
<surname>Arsenault</surname>
<given-names>BJ</given-names>
</string-name>, <string-name>
<surname>Mora</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Pedersen</surname>
<given-names>TR</given-names>
</string-name>, <string-name>
<surname>LaRosa</surname>
<given-names>JC</given-names>
</string-name>, <string-name>
<surname>Nestel</surname>
<given-names>PJ</given-names>
</string-name>, <string-name>
<surname>Simes</surname>
<given-names>RJ</given-names>
</string-name>, <string-name>
<surname>Durrington</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Hitman</surname>
<given-names>GA</given-names>
</string-name>, <string-name>
<surname>Welch</surname>
<given-names>KM</given-names>
</string-name>, <string-name>
<surname>DeMicco</surname>
<given-names>DA</given-names>
</string-name>, <string-name>
<surname>Zwinderman</surname>&#x000a0;<given-names>AH</given-names>
</string-name>, <string-name>
<surname>Clearfield</surname>
<given-names>MB</given-names>
</string-name>, <string-name>
<surname>Downs</surname>
<given-names>JR</given-names>
</string-name>, <string-name>
<surname>Tonkin</surname>
<given-names>AM</given-names>
</string-name>, <string-name>
<surname>Colhoun</surname>
<given-names>HM</given-names>
</string-name>, <string-name>
<surname>Gotto</surname>
<given-names>AM</given-names>
<suffix>Jr</suffix>
</string-name>, <string-name>
<surname>Ridker</surname>
<given-names>PM</given-names>
</string-name>, <string-name>
<surname>Kastelein</surname>
<given-names>JJ</given-names>
</string-name>. <article-title>Association of LDL cholesterol, non&#x02010;HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta&#x02010;analysis</article-title>. <source>JAMA</source>. <year>2012</year>;<volume>307</volume>:<fpage>1302</fpage>&#x02013;<lpage>1309</lpage>.<pub-id pub-id-type="pmid">22453571</pub-id></mixed-citation></ref><ref id="jah32370-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="jah32370-cit-0008">
<string-name>
<surname>Mora</surname>
<given-names>S</given-names>
</string-name>. <article-title>Advanced lipoprotein testing and subfractionation are not (yet) ready for routine clinical use</article-title>. <source>Circulation</source>. <year>2009</year>;<volume>119</volume>:<fpage>2396</fpage>&#x02013;<lpage>2404</lpage>.<pub-id pub-id-type="pmid">19414657</pub-id></mixed-citation></ref><ref id="jah32370-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="jah32370-cit-0009">
<string-name>
<surname>Jeyarajah</surname>
<given-names>EJ</given-names>
</string-name>, <string-name>
<surname>Cromwell</surname>
<given-names>WC</given-names>
</string-name>, <string-name>
<surname>Otvos</surname>
<given-names>JD</given-names>
</string-name>. <article-title>Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy</article-title>. <source>Clin Lab Med</source>. <year>2006</year>;<volume>26</volume>:<fpage>847</fpage>&#x02013;<lpage>870</lpage>.<pub-id pub-id-type="pmid">17110242</pub-id></mixed-citation></ref><ref id="jah32370-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="jah32370-cit-0010">
<string-name>
<surname>Ridker</surname>
<given-names>PM</given-names>
</string-name>, <string-name>
<surname>Danielson</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Fonseca</surname>
<given-names>FA</given-names>
</string-name>, <string-name>
<surname>Genest</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Gotto</surname>
<given-names>AM</given-names>
<suffix>Jr</suffix>
</string-name>, <string-name>
<surname>Kastelein</surname>
<given-names>JJ</given-names>
</string-name>, <string-name>
<surname>Koenig</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Libby</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Lorenzatti</surname>
<given-names>AJ</given-names>
</string-name>, <string-name>
<surname>MacFadyen</surname>
<given-names>JG</given-names>
</string-name>, <string-name>
<surname>Nordestgaard</surname>
<given-names>BG</given-names>
</string-name>, <string-name>
<surname>Shepherd</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Willerson</surname>
<given-names>JT</given-names>
</string-name>, <string-name>
<surname>Glynn</surname>
<given-names>RJ</given-names>
</string-name>; <collab collab-type="authors">JUPITER Study Group</collab>
. <article-title>Rosuvastatin to prevent vascular events in men and women with elevated C&#x02010;reactive protein</article-title>. <source>N Engl J Med</source>. <year>2008</year>;<volume>359</volume>:<fpage>2195</fpage>&#x02013;<lpage>2207</lpage>.<pub-id pub-id-type="pmid">18997196</pub-id></mixed-citation></ref><ref id="jah32370-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="jah32370-cit-0011">
<string-name>
<surname>Glynn</surname>
<given-names>RJ</given-names>
</string-name>, <string-name>
<surname>MacFadyen</surname>
<given-names>JG</given-names>
</string-name>, <string-name>
<surname>Ridker</surname>
<given-names>PM</given-names>
</string-name>. <article-title>Tracking of high&#x02010;sensitivity C&#x02010;reactive protein after an initially elevated concentration: the JUPITER Study</article-title>. <source>Clin Chem</source>. <year>2009</year>;<volume>55</volume>:<fpage>305</fpage>&#x02013;<lpage>312</lpage>.<pub-id pub-id-type="pmid">19095726</pub-id></mixed-citation></ref><ref id="jah32370-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="jah32370-cit-0012">
<string-name>
<surname>Mora</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Glynn</surname>
<given-names>RJ</given-names>
</string-name>, <string-name>
<surname>Boekholdt</surname>
<given-names>SM</given-names>
</string-name>, <string-name>
<surname>Nordestgaard</surname>
<given-names>BG</given-names>
</string-name>, <string-name>
<surname>Kastelein</surname>
<given-names>JJ</given-names>
</string-name>, <string-name>
<surname>Ridker</surname>
<given-names>PM</given-names>
</string-name>. <article-title>On&#x02010;treatment non&#x02010;high&#x02010;density lipoprotein cholesterol, apolipoprotein B, triglycerides, and lipid ratios in relation to residual vascular risk after treatment with potent statin therapy: JUPITER (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin)</article-title>. <source>J Am Coll Cardiol</source>. <year>2012</year>;<volume>59</volume>:<fpage>1521</fpage>&#x02013;<lpage>1528</lpage>.<pub-id pub-id-type="pmid">22516441</pub-id></mixed-citation></ref><ref id="jah32370-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="jah32370-cit-0013">
<string-name>
<surname>Varbo</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Nordestgaard</surname>
<given-names>BG</given-names>
</string-name>. <article-title>Remnant cholesterol and ischemic heart disease</article-title>. <source>Curr Opin Lipidol</source>. <year>2014</year>;<volume>25</volume>:<fpage>266</fpage>&#x02013;<lpage>273</lpage>.<pub-id pub-id-type="pmid">24977981</pub-id></mixed-citation></ref><ref id="jah32370-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="jah32370-cit-0014">
<string-name>
<surname>Mora</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Otvos</surname>
<given-names>JD</given-names>
</string-name>, <string-name>
<surname>Rifai</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Rosenson</surname>
<given-names>RS</given-names>
</string-name>, <string-name>
<surname>Buring</surname>
<given-names>JE</given-names>
</string-name>, <string-name>
<surname>Ridker</surname>
<given-names>PM</given-names>
</string-name>. <article-title>Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women</article-title>. <source>Circulation</source>. <year>2009</year>;<volume>119</volume>:<fpage>931</fpage>&#x02013;<lpage>939</lpage>.<pub-id pub-id-type="pmid">19204302</pub-id></mixed-citation></ref><ref id="jah32370-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="jah32370-cit-0015">
<string-name>
<surname>Shah</surname>
<given-names>SH</given-names>
</string-name>, <string-name>
<surname>Granger</surname>
<given-names>CB</given-names>
</string-name>, <string-name>
<surname>Hauser</surname>
<given-names>ER</given-names>
</string-name>, <string-name>
<surname>Kraus</surname>
<given-names>WE</given-names>
</string-name>, <string-name>
<surname>Sun</surname>
<given-names>JL</given-names>
</string-name>, <string-name>
<surname>Pieper</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Nelson</surname>
<given-names>CL</given-names>
</string-name>, <string-name>
<surname>Delong</surname>
<given-names>ER</given-names>
</string-name>, <string-name>
<surname>Califf</surname>
<given-names>RM</given-names>
</string-name>, <string-name>
<surname>Newby</surname>
<given-names>LK</given-names>
</string-name>; <collab collab-type="authors">MURDOCK Horizon 1 Cardiovascular Disease Investigators</collab>
. <article-title>Reclassification of cardiovascular risk using integrated clinical and molecular biosignatures: design of and rationale for the Measurement to Understand the Reclassification of Disease of Cabarrus and Kannapolis (MURDOCK) Horizon 1 Cardiovascular Disease Study</article-title>. <source>Am Heart J</source>. <year>2010</year>;<volume>160</volume>:<fpage>371</fpage>&#x02013;<lpage>379</lpage>.e372.<pub-id pub-id-type="pmid">20826242</pub-id></mixed-citation></ref><ref id="jah32370-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="jah32370-cit-0016">
<string-name>
<surname>Mora</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Szklo</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Otvos</surname>
<given-names>JD</given-names>
</string-name>, <string-name>
<surname>Greenland</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Psaty</surname>
<given-names>BM</given-names>
</string-name>, <string-name>
<surname>Goff</surname>
<given-names>DC</given-names>
<suffix>Jr</suffix>
</string-name>, <string-name>
<surname>O'Leary</surname>
<given-names>DH</given-names>
</string-name>, <string-name>
<surname>Saad</surname>
<given-names>MF</given-names>
</string-name>, <string-name>
<surname>Tsai</surname>
<given-names>MY</given-names>
</string-name>, <string-name>
<surname>Sharrett</surname>
<given-names>AR</given-names>
</string-name>. <article-title>LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the Multi&#x02010;Ethnic Study of Atherosclerosis (MESA)</article-title>. <source>Atherosclerosis</source>. <year>2007</year>;<volume>192</volume>:<fpage>211</fpage>&#x02013;<lpage>217</lpage>.<pub-id pub-id-type="pmid">16765964</pub-id></mixed-citation></ref><ref id="jah32370-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="jah32370-cit-0017">
<string-name>
<surname>Sabatine</surname>
<given-names>MS</given-names>
</string-name>, <string-name>
<surname>Giugliano</surname>
<given-names>RP</given-names>
</string-name>, <string-name>
<surname>Keech</surname>
<given-names>AC</given-names>
</string-name>, <string-name>
<surname>Honarpour</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Wiviott</surname>
<given-names>SD</given-names>
</string-name>, <string-name>
<surname>Murphy</surname>
<given-names>SA</given-names>
</string-name>, <string-name>
<surname>Kuder</surname>
<given-names>JF</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Wasserman</surname>
<given-names>SM</given-names>
</string-name>, <string-name>
<surname>Sever</surname>
<given-names>PS</given-names>
</string-name>, <string-name>
<surname>Pedersen</surname>
<given-names>TR</given-names>
</string-name>; <collab collab-type="authors">FOURIER Investigators</collab>
. <article-title>Evolocumab and clinical outcomes in patients with cardiovascular disease</article-title>. <source>N Engl J Med</source>. <year>2017</year>;<volume>376</volume>:<fpage>1713</fpage>&#x02013;<lpage>1722</lpage>.<pub-id pub-id-type="pmid">28304224</pub-id></mixed-citation></ref><ref id="jah32370-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="jah32370-cit-0018">
<string-name>
<surname>Khera</surname>
<given-names>AV</given-names>
</string-name>, <string-name>
<surname>Everett</surname>
<given-names>BM</given-names>
</string-name>, <string-name>
<surname>Caulfield</surname>
<given-names>MP</given-names>
</string-name>, <string-name>
<surname>Hantash</surname>
<given-names>FM</given-names>
</string-name>, <string-name>
<surname>Wohlgemuth</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Ridker</surname>
<given-names>PM</given-names>
</string-name>, <string-name>
<surname>Mora</surname>
<given-names>S</given-names>
</string-name>. <article-title>Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin)</article-title>. <source>Circulation</source>. <year>2014</year>;<volume>129</volume>:<fpage>635</fpage>&#x02013;<lpage>642</lpage>.<pub-id pub-id-type="pmid">24243886</pub-id></mixed-citation></ref><ref id="jah32370-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="jah32370-cit-0019">
<string-name>
<surname>Varbo</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Nordestgaard</surname>
<given-names>BG</given-names>
</string-name>. <article-title>Remnant cholesterol and triglyceride&#x02010;rich lipoproteins in atherosclerosis progression and cardiovascular disease</article-title>. <source>Arterioscler Thromb Vasc Biol</source>. <year>2016</year>;<volume>36</volume>:<fpage>2133</fpage>&#x02013;<lpage>2135</lpage>.<pub-id pub-id-type="pmid">27784698</pub-id></mixed-citation></ref><ref id="jah32370-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="jah32370-cit-0020">
<string-name>
<surname>Nakajima</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Nakano</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Tanaka</surname>
<given-names>A</given-names>
</string-name>. <article-title>The oxidative modification hypothesis of atherosclerosis: the comparison of atherogenic effects on oxidized LDL and remnant lipoproteins in plasma</article-title>. <source>Clin Chim Acta</source>. <year>2006</year>;<volume>367</volume>:<fpage>36</fpage>&#x02013;<lpage>47</lpage>.<pub-id pub-id-type="pmid">16448638</pub-id></mixed-citation></ref><ref id="jah32370-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="jah32370-cit-0021">
<string-name>
<surname>Parish</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Offer</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Clarke</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Hopewell</surname>
<given-names>JC</given-names>
</string-name>, <string-name>
<surname>Hill</surname>
<given-names>MR</given-names>
</string-name>, <string-name>
<surname>Otvos</surname>
<given-names>JD</given-names>
</string-name>, <string-name>
<surname>Armitage</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Collins</surname>
<given-names>R</given-names>
</string-name>; <collab collab-type="authors">Heart Protection Study Collaborative Group</collab>
. <article-title>Lipids and lipoproteins and risk of different vascular events in the MRC/BHF Heart Protection Study</article-title>. <source>Circulation</source>. <year>2012</year>;<volume>125</volume>:<fpage>2469</fpage>&#x02013;<lpage>2478</lpage>.<pub-id pub-id-type="pmid">22539783</pub-id></mixed-citation></ref><ref id="jah32370-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="jah32370-cit-0022">
<string-name>
<surname>Miller</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Stone</surname>
<given-names>NJ</given-names>
</string-name>, <string-name>
<surname>Ballantyne</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Bittner</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Criqui</surname>
<given-names>MH</given-names>
</string-name>, <string-name>
<surname>Ginsberg</surname>
<given-names>HN</given-names>
</string-name>, <string-name>
<surname>Goldberg</surname>
<given-names>AC</given-names>
</string-name>, <string-name>
<surname>Howard</surname>
<given-names>WJ</given-names>
</string-name>, <string-name>
<surname>Jacobson</surname>
<given-names>MS</given-names>
</string-name>, <string-name>
<surname>Kris&#x02010;Etherton</surname>
<given-names>PM</given-names>
</string-name>, <string-name>
<surname>Lennie</surname>
<given-names>TA</given-names>
</string-name>, <string-name>
<surname>Levi</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Mazzone</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Pennathur</surname>
<given-names>S</given-names>
</string-name>; <collab collab-type="authors">American Heart Association Clinical Lipidology, Thrombosis, and Prevention Committee of the Council on Nutrition, Physical Activity, and Metabolism; Council on Arteriosclerosis, Thrombosis, and Vascular Biology; Council on Cardiovascular Nursing; Council on the Kidney in Cardiovascular Disease</collab>
. <article-title>Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association</article-title>. <source>Circulation</source>. <year>2011</year>;<volume>123</volume>:<fpage>2292</fpage>&#x02013;<lpage>2333</lpage>.<pub-id pub-id-type="pmid">21502576</pub-id></mixed-citation></ref><ref id="jah32370-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="jah32370-cit-0023">
<string-name>
<surname>Wurtz</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>Q</given-names>
</string-name>, <string-name>
<surname>Soininen</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Kangas</surname>
<given-names>AJ</given-names>
</string-name>, <string-name>
<surname>Fatemifar</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Tynkkynen</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Tiainen</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Perola</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Tillin</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Hughes</surname>
<given-names>AD</given-names>
</string-name>, <string-name>
<surname>Mantyselka</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Kahonen</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Lehtimaki</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Sattar</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Hingorani</surname>
<given-names>AD</given-names>
</string-name>, <string-name>
<surname>Casas</surname>
<given-names>JP</given-names>
</string-name>, <string-name>
<surname>Salomaa</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Kivimaki</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Jarvelin</surname>
<given-names>MR</given-names>
</string-name>, <string-name>
<surname>Davey Smith</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Vanhala</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Lawlor</surname>
<given-names>DA</given-names>
</string-name>, <string-name>
<surname>Raitakari</surname>
<given-names>OT</given-names>
</string-name>, <string-name>
<surname>Chaturvedi</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Kettunen</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Ala&#x02010;Korpela</surname>
<given-names>M</given-names>
</string-name>. <article-title>Metabolomic profiling of statin use and genetic&#x000a0;inhibition of HMG&#x02010;CoA reductase</article-title>. <source>J Am Coll Cardiol</source>. <year>2016</year>;<volume>67</volume>:<fpage>1200</fpage>&#x02013;<lpage>1210</lpage>.<pub-id pub-id-type="pmid">26965542</pub-id></mixed-citation></ref><ref id="jah32370-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="jah32370-cit-0024">
<string-name>
<surname>Mora</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Caulfield</surname>
<given-names>MP</given-names>
</string-name>, <string-name>
<surname>Wohlgemuth</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Superko</surname>
<given-names>HR</given-names>
</string-name>, <string-name>
<surname>Rowland</surname>
<given-names>CM</given-names>
</string-name>, <string-name>
<surname>Glynn</surname>
<given-names>RJ</given-names>
</string-name>, <string-name>
<surname>Ridker</surname>
<given-names>PM</given-names>
</string-name>, <string-name>
<surname>Krauss</surname>
<given-names>RM</given-names>
</string-name>. <article-title>Atherogenic lipoprotein subfractions determined by ion mobility and first cardiovascular events after random allocation to high&#x02010;intensity statin or placebo: the justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER) trial</article-title>. <source>Circulation</source>. <year>2015</year>;<volume>132</volume>:<fpage>2220</fpage>&#x02013;<lpage>2229</lpage>.<pub-id pub-id-type="pmid">26408274</pub-id></mixed-citation></ref><ref id="jah32370-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="jah32370-cit-0025">
<string-name>
<surname>Williams</surname>
<given-names>PT</given-names>
</string-name>, <string-name>
<surname>Zhao</surname>
<given-names>XQ</given-names>
</string-name>, <string-name>
<surname>Marcovina</surname>
<given-names>SM</given-names>
</string-name>, <string-name>
<surname>Otvos</surname>
<given-names>JD</given-names>
</string-name>, <string-name>
<surname>Brown</surname>
<given-names>BG</given-names>
</string-name>, <string-name>
<surname>Krauss</surname>
<given-names>RM</given-names>
</string-name>. <article-title>Comparison of four methods of analysis of lipoprotein particle subfractions for their association with angiographic progression of coronary artery disease</article-title>. <source>Atherosclerosis</source>. <year>2014</year>;<volume>233</volume>:<fpage>713</fpage>&#x02013;<lpage>720</lpage>.<pub-id pub-id-type="pmid">24603218</pub-id></mixed-citation></ref><ref id="jah32370-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="jah32370-cit-0026">
<string-name>
<surname>Chapman</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Ginsberg</surname>
<given-names>HN</given-names>
</string-name>, <string-name>
<surname>Amarenco</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Andreotti</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Boren</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Catapano</surname>
<given-names>AL</given-names>
</string-name>, <string-name>
<surname>Descamps</surname>
<given-names>OS</given-names>
</string-name>, <string-name>
<surname>Fisher</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Kovanen</surname>
<given-names>PT</given-names>
</string-name>, <string-name>
<surname>Kuivenhoven</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Lesnik</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Masana</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Nordestgaard</surname>
<given-names>BG</given-names>
</string-name>, <string-name>
<surname>Ray</surname>
<given-names>KK</given-names>
</string-name>, <string-name>
<surname>Reiner</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Taskinen</surname>
<given-names>MR</given-names>
</string-name>, <string-name>
<surname>Tokgozoglu</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Tybjaerg&#x02010;Hansen</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Watts</surname>
<given-names>GF</given-names>
</string-name>; <collab collab-type="authors">European Atherosclerosis Society Consensus Panel</collab>
. <article-title>Triglyceride&#x02010;rich lipoproteins and high&#x02010;density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management</article-title>. <source>Eur Heart J</source>. <year>2011</year>;<volume>32</volume>:<fpage>1345</fpage>&#x02013;<lpage>1361</lpage>.<pub-id pub-id-type="pmid">21531743</pub-id></mixed-citation></ref><ref id="jah32370-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="jah32370-cit-0027">
<string-name>
<surname>Michos</surname>
<given-names>ED</given-names>
</string-name>, <string-name>
<surname>Blumenthal</surname>
<given-names>RS</given-names>
</string-name>. <article-title>Prevalence of low low&#x02010;density lipoprotein cholesterol with elevated high sensitivity C&#x02010;reactive protein in the U.S.: implications of the JUPITER (justification for the use of statins in primary prevention: an intervention trial evaluating rosuvastatin) study</article-title>. <source>J Am Coll Cardiol</source>. <year>2009</year>;<volume>53</volume>:<fpage>931</fpage>&#x02013;<lpage>935</lpage>.<pub-id pub-id-type="pmid">19281922</pub-id></mixed-citation></ref></ref-list></back></article>